Prevalence and determinants of non-barrier contraceptive use in HIV-positive women who attend HIV services at public sector clinics in Gugulethu by Maksimoski, Nancy
The copyright of this thesis rests with the University of Cape Town. No 
quotation from it or information derived from it is to be published 
without full acknowledgement of the source. The thesis is to be used 











Prevalence and determinants of non-barrier contraceptive
use in HIV-positive women who attend HIV services at
public sector clinics in Gugulethu
In partial fulfilment of the requirements for the degree of Masters of Philosophy in
Public Health (specialisation epidemiology and biostatistics)
Nancy Maksimoski
MKSNAN001

















South Africa has one of the highest prevalences of HIV-infection in women of
reproductive age and a high rate of unplanned pregnancy. It is important to explore
contraceptive use in HIV-positive women to better understand how to facilitate
service delivery to those women wishing to avoid pregnancy.  While it is critical to
emphasise condom use, information is needed on the factors that contribute to non-
barrier contraceptive use (NBCU) and its prevalence among HIV-positive women in
order to afford women the opportunity to choose to have maximum dual method
protection to prevent both infection and unwanted pregnancy.  While there is
literature on people living with AIDS and contraceptive use from other areas of the
world, there is little quantitative research conducted  in a South African context,
although there is evidence of a high proportion of unwanted pregnancy among HIV-
positive women in this setting.
Rationale and Justification for Research
Information is needed to understand the factors that contribute to NBCU by HIV-
positive women, including the prevalence of these determinants.  By better
understanding the obstacles to non-barrier contraceptive use, both HIV and
reproductive health services will better be able to provide more appropriate
contraceptive health care to HIV-positive women.
Aims
The aim of this study is to determine the prevalence of NBCU and the types of
methods used innon-pregnant, HIV-positive women, and to determine the factors that
influence the choice of NBCU.
Objectives
To determine the prevalence of NBCU in a population of HIV-positive South African
females; To determine what factors influence NBCU in women infected with HIV,
including whether or not NBCU changes after an HIV-positive diagnosis; To compare












those who do not want children in the future, and who are currently on antiretroviral
therapy (ART) to those who are not currently on ART; To determine what factors
influence NBCU for particular subsets of women, including those with and without
fertility intentions in the next 12 months and women currently on and not on ART; To
determine the unmet need for non-barrier contraception in HIV-positive women.
Methods
This study will form  a part of  a larger cross-sectional study, which collected data on
the fertility intentions and the utilization of HIV and reproductive health services of
459 HIV-seropositive men and women from the peri-urban informal settlement of
Gugulethu, located outside of Cape Town, from May to September 2006.  Data was
collected by trained fieldworkers through the use of a standardised quantitative survey
instrument.  A qualitative study consisting of in-depth interviews and focus groups
with HIV-infected men was also conducted as part of the larger research project.
After being cleaned, data was transferred to STATA Release 10 (STATACorp,
College Station, USA) where bi-variate and multi-variate statistical analysis was
performed.
Ethics
The Ethical Review Committee of the World Health Organisation and the Research
Ethics Committee of the University of Cape Town, the research partners in this study,
granted ethical approval to the larger cross-sectional study to which this sub-study is
part.  All participants who agreed to the voluntary interview provided informed
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South Africa has one of  the largest populations of HIV-infected persons in the world,
at an estimated 5.7 million people (UNAIDS, 2008).  The vast majority of those
infected are in their reproductive years, with a disproportionate number of females
being infected (UNAIDS, 2008).  Thanks to the introduction of ART and PMTCT,
people with HIV/AIDS are living longer and women are much less likely to transmit
the virus to their children in utero and while breastfeeding (da Silveira Rossi, et al,
2005, Williams, et al, 2003)  An estimated 29.3% of pregnant women are infected
with HIV (Department of Health, 2009).
There is inconclusive evidence  from around the globe as to whether there is an
association between a reduction in fertility and a female’s sero-positive HIV status
(Magalhães, et al, 2002, Thackway,  et al, 1997,  Delvaux & Nöstlinger, 2007),
with diversity in fertility intentions (Meursing & Sibindi, 1995; Smits, et al. 1999;
Chen, et al. 2001; Nebie,et al, 2001; Kirshenbaum et al. 2004)  More recent
evidence seems to indicate that an HIV positive diagnosis is not necessarily the
key determining factor in whether HIV positive people decide whether to have
(further) children or not. A recent study in South Africa found that an almost
similar proportion of the HIV-positive women and men attending an HIV care
centre intended to have biological children at some stage as did not intend having
children (Cooper,  et al, 2009).
Globally, over half of all pregnancies in the general population of women are
unintentional, which suggests a large unmet need for contraceptive services (Cates
& Steiner, 2002). International research shows that sero-positive women have a
high rate of unplanned pregnancy (Mitchell & Stephens, 2004).  In  a study of
HIV infected individuals in South Africa in HIV care, 11% reported becoming
pregnant after being aware of their HIV status and all these pregnancies were
reportedly unintentional . Among women on highly active antiretroviral therapy
(HAART), 9% reported having been pregnant since commencing HAART and of












AIDS related causes are the main cause of maternal death in South Africa
(Department of Health, 2009b) and a recent study found that very ill HIV
–positive women were seven times more likely to die in childbirth than other high
risk pregnant women (Black et al, 2009).  It is important to assist women in
general to avoid unintentional pregnancies through providing information and
access to contraception. However, tthe findings on unintended pregnancies among
HIV-positive women, in light of the high maternal mortality rates among women
living with HIV whose immune system has become severely compromised,  adds
urgency to the issue of ensuring that women living with HIV (WLH) in South
Africa are able to optimise access to contraception should they wish to avoid
pregnancy .. Clearly interventions to address the gaps in contraceptive needs is
required both in the broader reproductive health services and within HIV care
settings. Lack of easy access to contraceptive measures may lead to pregnancies
occurring in the most unsafe conditions and clients’ desires to prevent or
discontinue pregnancies will not be met.
Despite evidence of the high prevalence of HIV/AIDS and unplanned pregnancy in
South Africa, little information is available on Non-Barrier Contraceptive Use
(NBCU) by HIV-positive women in the country.  In 2003, globally of the 5.2 million
women who were married or regularly cohabitating, 55.6% were currently using NBC
and 15% of this population alone had an unmet need for family planning (United
Nations Department of Economic and Social Affairs, 2007).  In South Africa, where
there is relatively high ever contraceptive use (61%) relative to other countries in
Southern Africa, the majority of women (71%) only use contraceptives once they
have had a first child (South African Demographic and Health Survey, 2001).  In
addition, 35% of teenagers have been pregnant by age 19 years and 98% of teenage
pregnancies are unintended. In South Africa, 74% of the general population of women
using contraception, used a hormonal contraceptive methods (either the injectable or
the pill) versus 4% condom use to avoid pregnancy (Rees, 2008).  There is very
limited information on contraceptive use and especially NBCU and knowledge of
what factors contribute to NBCU in HIV-positive women. Adding to our knowledge












HIV and reproductive health services, but also for creating national programmes to
promote the use of NBC by HIV-positive women to prevent unintended pregnancies.
1.1.1 Non-Barrier vs. Barrier Methods of Contraception
Reasons for Use
Sexually active persons tend to use contraception for one or both of two reasons:
to prevent the transmission/acquisition of STIs and HIV/AIDS and to prevent
unwanted pregnancy (Cates & Steiner, 2002).  Barrier methods (male and female
condoms) are the most effective forms of contraception for preventing the
transmission of infection, but are not the most effective forms of contraception for
preventing pregnancy, due to incorrect and inconsistent use (Mitchell & Stephens,
2004).  Contrastingly, non-barrier methods of contraception (sterilisation [male
and female], oral pills, injectables, implants, and intrauterine devices) are most
effective at avoiding pregnancy, but much less effective at preventing infection.
The use of contraception to prevent both STI transmission and pregnancy is
known either as dual protection (Myer, et al, 2002) when barrier methods are used
to prevent both or when both barrier methods and a NBC method are used
concomitantly.  
Given the massive proportion of the HIV epidemic in South Africa and the
endemic nature of STI’s,  if only one method is going to be used, health
professionals within HIV or STI care and treatment, may advocate that those at
high risk of STI infection use condoms. On the other hand, sexual and
reproductive health services if they are unware of a client’s HIV status may
promote primarily a NBC method to prevent pregnancy with condom- back up use
until this is effective. Clients and couples with steady partners are likely to have
diverse needs with some being most concerned about an unintended pregnancy,
while others  may be more worried about contracting STIs (Cates & Steiner,
2002).
Negotiating Contraception
In many developing countries, including South Africa, there is evidence that many












partner (Santos, et al, 1998, Feldman & Maposhere, 2003, Delvaux & Nöstingler,
2007).  Sexual and reproductive health (SRH) services apart from STI’s tend to be
seen as a ‘women’s area’ and it has been difficult to involve a general population
of men in SRH services. Some men may also disapprove of their female partners
using a contraceptive method (Cooper et al, 2004) and women may therefore,
consider  it important to have the opportunity to use contraceptive methods that
are not reliant on the male partner, but are controlled by the woman herself.  Other
than the female condom and the potential promise of microbicides in the future,
these women-controlled methods are mainly of the non-barrier form. While they
do not protect against infection unless used together with barrier methods, they are
very effective at preventing pregnancy if taken correctly (Cates & Steiner, 2002).
Hence in the South African context there is a need among all women and
especially HIV positive women, given the potential risks of pregnancy if they are
ill, to have access to to different forms of NBC, as well as barrier methods.
In South Africa, in particular, there is a lack of information about the use of non-
barrier methods of contraception by HIV-positive women, as many of the
governmental policies for WLH have focused on the promotion of barrier
methods.  Combined with the fact that ART allows sero-positive persons to live
longer as well as reduces the risk of MTCT, family planning is not only relevant
to HIV-positive women, but it is vital that these women are given proper
counselling on issues surrounding the topic. Also important to HIV-positive
women are the concern of STI and HIV/AIDS transmission.  Contracting an STI
can not only worsen the woman’s condition, but may also make her more
infective when having intercourse.  It imperative to gain greater knowledge on the
use of NBC in HIV-positive women in order to better aid them with reproductive
and HIV-services.
1.1.2 Factors Associated with NBCU
Sociodemographic Factors
Like the general population, an HIV-positive woman’s need for contraception will
change over the course of her life, which may suggest that NBCU may be












found that level of education is positively associated with NBCU (Allen, et al,
1993, Mitchell & Stephens, 2004).
Factors Associated with Diagnosis
Research from Brazil and a variety of other countries (Magalhães, et al, 2002,
Meursing & Sibindi, 1995; Smits, et al. 1999; Chen, et al. 2001; Nebie,et al, 2001;
Kirshenbaum et al. 2004)  suggests that an HIV-positive diagnosis can impact on
both women and men’s  sex lives.  Knowledge of a positive sero-status may cause
the woman to feel more uncomfortable about sexual intercourse, resulting in
reduced sexual activity (Santos, et al, 1998).  However, as the women become
more comfortable with their sero-status and particularly if they become well again
on HAART, they may increase their sexual activity. This increases their need for
both barrier and non-barrier contraceptive methods.  Other Brazilian research
showed that women’s contraception use changed in a statistically significant way,
following an HIV-positive diagnosis (Magalhães, et al, 2002)
Drug Interactions
Many of the NBC methods are hormonal in nature. Although more research is
necessary, it is suggested that the protease inhibitors and non-nucleoside reverse
transcriptase inhibitors found in some types of HAART, such as Nevirapine,
interact with  the levels of steroids in hormonal contraceptive pills, causing the
method to be less effective. This interaction seems to be particular to the pill, as
HAART does not appear to reduce the efficacy of the injectable depot
medroxyprogesterone acetate (DMPA)  (El-Ibiary & Cocohoba, 2008). Therefore,
clinicians suggest that women on the pill use a barrier method to help prevent
unwanted pregnancy (Cejtin, 2003, Mitchell & Stephens, 2004), although it may
be possible to take a non-ritonavir boosted atazanavir or non-ritonavir boosted
indinavir to increase the contraceptive efficacy of the pill when taken with
HAART (El-Ibiary & Cocochoba, 2008) .  Similarly, there is an interaction
between the pill and tuberculosis (TB) drug Rifampicin, in which use of
Rifampicin causes the pill to be less effective (Cejtin, 2003, Mitchell & Stephens,
2004).  This is particularly problematic in the South African context, as South












(948 cases per 100,000 people) of TB with extremely high co-infection rates of
HIV and TB. Of the 73% incident cases of TB, half  are HIV-positive (World
Health Organisation, 2009). Hormonal oral contraceptive may also be less
effective if taken concomitantly with Rifabutin (used for TB treatment), certain
epilepsy drugs (Phenytoin,Carbamazepine, barbiturates, Primidone, Topiramate,
Oxcarbazepine, Lamotrigine) or antiretroviral drugs Ritonavir and Efavirenz
(World Health Organisation, 2008). Due to its possible reduced efficacy, HIV-
positive women on ART or Rifampicin may be advised not to use the pill or may
themselves believe that the method is not worth taking, and may therefore have a
lower prevalence of NBCU than HIV-positive women who are TB-negative and
not on ART.  Issues have also been raised about the possible complications of
intra-uterine device (IUD) use in HIV-positive women, such as an increased risk
of acute pelvic inflammatory disease (Cetjin, 2003, Mitchells & Stephens, 2004).
However, recent evidence suggests that except for individuals with particular
circumstances, use of the IUD is not only safe, but effective, for HIV-positive
women (Stringer, et al, 2007).
Relationship Status
Existing evidence from studies in other countries on the association between a
WLH’s relationship status and her NBCU is mixed, with some claiming that the
length of the relationship does not appear to influence NBCU (Smits, et al, 1999),
while other evidence suggests that single women may be more likely to use
certain methods, such as injectables (Allen, et al, 1993). A study from Uganda
found a positive correlation between NBCU and the number of sexual partners
(Kiddugavu, et al, 2003).
Barrier Methods
Although dual protection is the ideal for HIV-positive women, as it helps to
prevent both STI and HIV/AIDS transmission and unwanted pregnancy, research
strongly suggests that adding a second method may be to the detriment of first
method (Cates & Steiner, 2002) (Mitchell & Stephens, 2004).  A study of 1232
WLH in the United States showed that women using more effective forms of












contraception [OR 1.44, 95% CI 1.00-2.08]), were less likely to use condoms than
women not using these contraception methods (Diaz, et al, 1999). It is not known
whether HIV-positive women who are using condoms may have a lower
prevalence of NBCU than HIV-positive women who do not use condoms or visa
versa.
Fertility and Children
Research from a study of HIV-positive women  in Brazil suggests that NBCU is
associated with  the woman’s number of living children, in terms of the
prevalence  of the method used (Magalhães, et al, 2002).  An American study
found that the fertility intentions of HIV-positive women (women who did not
wish to become pregnant) were associated with NBCU (Lindsay, et al, 1995).  A
woman’s fertility intentions would be expected logically to influence whether
contraception is used and the type of contraception used (i.e. barrier or non-
barrier) in terms of its perceived effectiveness in preventing pregnancy,
particularly in an HIV-positive context.
Access to NBCU
Researchers from a Rwandan study concluded that the low prevalence of
hormonal contraception in this country may be due to access issues, as nearly 50
percent of women who did not use such contraception said they would use
hormonal injectable contraceptives, if available (Allen, et al, 2003).  While access
to contraceptives in South Africa is likely to be better, it is not known what
contraceptive methods availability and access issues affect WLH in particular.
Issues of accessibility as well as affordability (of the contraceptive itself or
travelling to access it as in the case of South Africa) have been raised by other
researchers, who note that some forms of NBCU require regular interaction with
health services (Delvaux & Nöstlinger, 2007, Mitchell & Stephens, 2004).
1.1.3 Limitations of Existing Studies
As little research exists on the factors that affect NBCU in HIV-positive women,
particularly in a South African context.  The proposed study will add to the












in different countries such as Brazil, Rwanda, and the United States (Magalhães,
et al, 2002, Allen, et al, 1993, Diaz, et al, 1995).  However, it is difficult to
extrapolate these findings to South Africa, due to contextual issues (i.e. high
prevalence of tubal ligation in Brazil compared to South Africa and social
differences) (United Nations Department of Economic and Social Affairs, 2007).
There is general consensus internationally that more research on this topic in a
diversity of contexts  is needed (Allen, et al, 1993, Lindsay, et al, 1995, Delvaux
& Nöstlinger, 2007).
Many of the studies under review only focus on one aspect of the factors affecting
NBCU in HIV-positive women, such as pregnancy in HIV-positive women
compared to HIV-negative women, fertility in HIV-positive women, and broader
attitudes towards contraceptive uses in HIV-positive women, thus giving an
incomplete or inaccurate portrayal of unmet need for contraception, factors
influencing non-use and the types of methods used (Lindsay, et al, 1995,
Thackway, et al, 1997, Cejtin, 2003).  The proposed analysis  and paper will
encompass this  wide variety of issues that are related to NBCU in HIV-positive
women in Cape Town, South Africa.
1.2 Rationale and Justification
There is a lack of information on NBCU in HIV-positive females in a South African
context.  Knowledge of what factors influence NBCU in HIV-positive females would
be very beneficial to health researchers, as this information would help in
understanding the reproductive health needs of this population.  It will also aid in
creating health policy and improved service delivery of contraception to HIV-positive
women not wishing to become pregnant.  Most of the governmental policy on
contraception targeted at HIV-positive individuals has focused on the knowledge and
free distribution of male condoms, critical to prevent infection and re-infection.
However, less attention has been paid to ensuring NBC awareness, knowledge and
access to avoid unwanted pregnancies, which has especially dire consequences for
HIV-positive women, as they may compromise the health of an unwell HIV-positive













•An HIV-positive diagnosis changes a woman’s use of NBC.
•Prevalence of NBCU is lower among HIV-positive women than the general
South African population.
•Women who wish to have a child in the next 12 months have a lower prevalence
of NBCU than women who do not wish to have a child in the next 12 months.
•Women currently on ART have a higher prevalence of NBCU than women not
currently on ART.
•Reasons for an HIV-positive woman’s use of NBC include sociodemographic
factors, factors associated with HIV-diagnosis, potential drug interactions,
relationship status, use of male or female condoms, access to NBC, and her
fertility intentions.
1.4 Aims and Objectives
1.4.1 Aims
The aim of this study is to determine the prevalence of NBCU in HIV-positive
women from the township of Gugulethu, compared to the general South African
population, and to determine the factors that influence the choice to use NBC.
1.4.2 Objectives
The key objectives of this study are:
(i) To determine the prevalence of NBCU in a population of HIV-positive
South African women
(ii) To determine if an HIV-positive diagnosis influences NBCU
(iii) To determine what factors influence an HIV-positive woman’s decision












(iv) To determine and compare the prevalence of NBCU among HIV-positive
women who wish to have a child in the next 12 months to the prevalence
of NBCU in HIV-positive women who do not wish to have a child in the
next 12 months.
(v) To determine what factors influence NBCU in the subgroups of those
currently on ART and those not currently on ART, and those with fertility
intentions and those without, paying special attention to barrier methods as
a predictor for those not using NBC.
(vi) To determine if there is a large unmet need for NBC in HIV-positive
women and to make recommendations for health policy and guidelines
surrounding their contraceptive needs
2. METHODS
2.1 Study Design
The proposed study is a sub-set of a larger cross-sectional study by Cooper, et al
(2005), Fertility Intentions, contraceptive service needs and reproductive decision-
making among HIV-infected women and men in Cape Town, South Africa. that
analyzed fertility intentions, contraceptive service needs and reproductive decision
making of HIV-positive persons from Gugulethu, South Africa.  The interviews were
conducted from May to September 2006 at two public sector health care centres in
Gugulethu with VCT,  pMTCT, ART, and general HIV services.
2.2 Population and Sampling
Participation in the study was voluntary, and subjects were randomly sampled each
day from the health care centre’s patient register and approached to participate in the
survey.  These health care centres were located in Gugulethu, an area with a high
HIV-prevalence located outside of Cape Town, and served a mostly black, urban and
peri-urban, working class population.  The randomly selected patients were thought to
be representative of the population of Gugulethu that was seeking HIV-related health
care and services.  The final sample size of the study was 459 people, with an 88%












conducted at two different sites, it is not considered to be a cluster study because the
two health care centres were located in the same area and served the same population.
Two sites were used in order to reach the target sample size within the specified time
frame of the study.
2.3 Measurement
2.3.1 Instrument
A quantitative survey was developed for the use of interviewing subjects.  This
standardised instrument was administered to participants in their mother tongue
(isiXhosa) by trained same-sex interviewers, who had previous experience
working with HIV-infected individuals.  The survey included questions pertaining
to demographic and socioeconomic characteristics, partnership status and sexual
activity, HIV-infection and ART, use of and access to contraceptive and
reproductive health services,  and fertility intentions.  The questionnaire asked
women about their contraceptive use before and after HIV-positive diagnosis.
2.3.2 List of Variables
Outcome Variable
Current NBCU Use
Participant was currently using at least one type of NBC or patient was not using
at least one type of NBC.  NBC was defined as oral contraceptive pill, 2-month




Age: measured in years
Occupation: employed or unemployed
Education: highest level completed













Factors Associated with HIV-diagnosis
Years Since Diagnosis: Measured in years
ART Status: Patient currently on ART or patient currently not on ART
Contraception
NBCU Before Diagnosis: Patient used NBC before HIV-positive diagnosis or did
not use NBC before HIV-positive diagnosis
NBCU After Diagnosis: Patient used NBC after being diagnosed HIV-positive
diagnosis or patient did not use NBC after being diagnosed HIV-positive
Perceived Difficulty in Accessing NBC: Very easy, easy, difficult, very difficult,
or don’t know/unsure
Condom Use After Diagnosis: Patient has used male or female condoms since
HIV-positive diagnosis or patient has not used male or female condoms since
diagnosis
Relationship
Sexual Relationship Status: In a sexual relationship or not in a sexual relationship
Relationship Type: Married, living with boy/girlfriend, or living apart from
boy/girlfriend
Sexual partners in past 6 months: The number of sexual partners the woman has
had in the past 6 months
Children & Fertility Intentions
Living Children: The number of living children of the study participant
Fertility Intentions: Would like to have a child right now, maybe would like to
have a child in the next 12 months, maybe would like to have a child sometime in














Data from the cross-sectional survey was entered into a template using Microsoft
Access 2000, which allowed for anonymity of data.  Subsequently, data was
transferred to STATA Release 10 (STATACorp, College Station, USA), where it was
cleaned for analysis.  Cleaning processes included checking for problematic data
through frequency distributions and internal logic checks.
3.2 Statistical Methods
As this analysis is concerned with NBCU in HIV-positive women, all men (157) and
pregnant women (122) will be excluded from analysis, as they are believed to have
different contraceptive needs than non-pregnant women, leaving 180 women for
analysis in this report.  In order to determine which factors influence NBCU in HIV-
positive women, various logistic regression models (all HIV-positive women, HIV-
positive women with fertility intentions in next 12 months, HIV-positive women
without fertility intentions for the next 12 months, HIV-positive women on ART,
HIV-positive women not on ART) will be built using the various risk factors.  During
the model building process, variables will be added one at a time, and models will be
assessed on their goodness of fit and maximum likelihood.  The final models will be
validated by an analysis of their residuals.
To examine if NBCU changes before and after diagnosis, a McNemar’s test of
association will be calculated from a 2x2 table that examines NBCU Before (yes/no)
and NBCU After (yes/no) HIV diagnosis.
Before beginning the model building procedure, all variables will be explored in order
to determine the nature of each variable and its relationship with the outcome
variable, as well as its relationship with the other determinant variables and problems
in the data, if necessary.  For the continuous variables, histograms will be used to
assess normality, and summary statistics and box-and-whisker plots, stratified by
outcome, will be created to infer associations with the outcome.  Tabulated statistics














Table I for objective (i): Frequencies of NBCU before and after diagnosis
Frequency Percent
No Use Before, No Use
After
No Use Before, Use After
Use Before, No Use After
Use Before, Use After
Table II for objective  (ii): Determinants of NBCU in HIV-positive women



























  Very Easy or Easy
  Very Difficult or Difficult







  In a Sexual Relationship















  Living with
Boy/girlfriend
  Living Apart from
Boy/girlfriend






  Right Now
  May in Next 12 Months
  May Sometime in Future
  Do Not Want Children in
Future
  Don’t Know/Unsure
Table III for objective (iii): Prevalence of NBCU in HIV-positive women with and
without fertility intentions in the next 12 months
Frequency of NBCU Percent
May Want Children in
Next 12 Months
Do Not Want Children in
Next 12 Months
Table IV for objective (iv): Determinants of NBCU in HIV-positive women with and
without fertility intentions in the next 12 months
With Fertility Intentions Without Fertility
Intentions






































  Very Easy or Easy
  Very Difficult or Difficult







  In a Sexual Relationship




  Living with
Boy/girlfriend
  Living Apart from
Boy/girlfriend






  Right Now
  May in Next 12 Months
  May Sometime in Future
  Do Not Want Children in
Future
  Don’t Know/Unsure
Table V for objective (v): Women with possible unmet NBC needs




























4. ETHICS AND COMMUNICATION
4.1 Ethics
Ethical approval for larger study, of which this proposed study is a sub-set of, was
granted by the Ethical Review Committee of the World Health Organisation and the
Research Ethics Committee of the University of Cape Town, the research partners in
this study.
4.1.1 Respect for Persons
Participants in the study were given information about the project’s purposes and
content in their local language (isiXhosa) or English, as a way of disclosing
information in an understandable manner.  Participation in the study was
voluntary, and all those who agreed to take part in the project provided their
written informed consent.  Only those who were 18 years of age or older were
approached for questioning and participants were allowed to withdraw at any
point during the study.
4.1.2 Beneficence
Researchers attempted to minimise the potential risks of the study, which included
stigmatisation, discomfort, and emotional distress.  Same sex interviewers
administered the questionnaire in private rooms in order to make the participant
more comfortable and able to provide honest answers.  Researchers referred those
experiencing emotional distress to counselling.
Only those involved in the project will have access to questionnaires and no
identifying information will be recorded on the questionnaire, as a way of
ensuring confidentiality and anonymity.  The proposed study will keep the
anonymity of participants, as no identifying names or addresses are recorded in












Participants were monetarily compensated for any transport costs they incurred in
order to take part in the study.
The possible benefits to the participant are great, as well as for those infected with
HIV in Gugulethu and the greater Cape Town area.  The results from this analysis
will lead to greater knowledge of the aspects of NBCU in this population, which
will allow for a more effective delivery of reproductive health services by
providers in the area.
4.1.3 Justice
Researchers and the public will have access to the results of this study through its
dissemination in a report and an article for publication.  Relevant information will
also be distributed to policy makers, in order to guide them on health policy
surrounding NBCU in HIV-positive women.
4.2 Stakeholders
Stakeholders who are expected to have an interest in the outcome of the project
include: The Department of Health, the broader research community (both those in
South Africa and abroad), people living with HIV/AIDS, and those working HIV and
reproductive health services.
4.3 Reporting and Communication




March – September 2009 Proposal preparation
October 2009 Proposal preparation
Submission and approval  by













November 2009 Data Analysis
Dissertation write up
December 2009 Submission of final report to department
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South Africa has one of the largest populations of HIV-infected persons in the world,
at an estimated 5.7 million people (UNAIDS, 2008).  The vast majority of those
infected are in their reproductive years, with a disproportionate number of females
being infected (UNAIDS, 2008).  An estimated 29.3% of pregnant women are
infected with HIV (Department of Health, 2009).  However, due to the introduction of
antiretroviral therapy (ART) and prevention of mother-to-child transmission
(pMTCT), people with HIV/AIDS are living longer and pregnant women living with
HIV are much less likely to transmit the virus to their children in utero and while
breastfeeding (da Silveira Rossi, et al, 2005; Williams, et al, 2003)
There is inconclusive evidence from around the globe as to whether there is a
reduction in intentions to have children as a result of a woman’s sero-positive HIV
status (Magalhães, et al, 2002; Thackway, et al, 1997; Delvaux & Nöstlinger, 2007).
Existing studies indicate that an HIV-positive diagnosis is not necessarily the key
determining factor in whether HIV-positive people decide whether to have (further)
children or not, and that there is diversity in fertility intentions (Meursing & Sibindi,
1995; Smits, et al. 1999; Chen, et al. 2001; Nebie, et al, 2001; Kirshenbaum, et al.
2004).  A recent study in South Africa found that an almost similar proportion of the
HIV-positive women and men attending an HIV care centre intended to have
biological children at some stage as did not intend to have children (Cooper,  et al,
2009).  This underscores the need for reproductive services to address the specific
needs of both those women wishing to become pregnant more safely as well as those
wishing to avoid pregnancy either temporarily or permanently.
Unintentional pregnancy constitutes a problem independently of HIV/AIDS.
Globally, over half of all pregnancies in the general population of women are
unintentional, which suggests a large unmet need for contraceptive services in general
(Cates & Steiner, 2002).  In sub-Saharan Africa, an estimated 14 million unintended
pregnancies arise each year (Hubacher, et al, 2008).  In South Africa, where there is
relatively high ever contraceptive use among ever sexually active women (85.4%)












only use contraceptives once they have had a first child (South African Demographic
and Health Survey, 2007). South Africa has the second highest overall prevalence of
modern method contraceptive use amongst women who are married or cohabitating in
all of Africa, after the island of Reunion (United Nations Department of Economics &
Social Affairs, 2007).  These women also have a much higher prevalence of
injectables than the rest of the continent (28.4% vs 5.9%) (United Nations Department
of Economics & Social Affairs, 2007). South African women experience high rates of
unintended pregnancy, with 35% of teenagers reporting having been pregnant by age
19 years and 53% of pregnancies reportedly being either unplanned (36%) or
unwanted (17%) (Department of Health, 2001).  In Cape Town, an estimated 98% of
teenage pregnancies are unintended (Vundule, et al, 2001).
International research shows that sero-positive women, too, have a high rate of
unplanned pregnancy (Mitchell & Stephens, 2004).  In a study of HIV infected
individuals in South Africa in HIV care, 11% reported becoming pregnant after being
aware of their HIV status and all these pregnancies were reportedly unintentional.
Among women on highly active antiretroviral therapy (HAART), 9% reported having
been pregnant since commencing HAART and of these 30% of pregnancies were
reportedly unintentional (Cooper, et al, 2009).
AIDS related causes are the main cause of maternal death in South Africa
(Department of Health, 2009b), and a recent study found that very ill HIV–positive
women were seven times more likely to die in childbirth than other high risk pregnant
women (Black, et al, 2009).  It is important to assist women in general to avoid
unintentional pregnancies through providing information and access to contraception,
as the lifetime risk of maternal death in South Africa is an estimated 1 in 110,
compared to 1 in 7300 for developed regions (World Health Organisation, et al,
2007). However, the findings on unintended pregnancies among HIV-positive
women, in light of the high maternal mortality rates among women living with HIV
whose immune system has become severely compromised, adds urgency to the issue
of ensuring that women living with HIV (WLH) in South Africa are able to optimise
access to contraception, should they wish to avoid pregnancy. Lack of adequate
knowledge, counselling or easy access to contraception may lead to pregnancies












pregnancies will not be met. On the other hand, increased use of effective
contraception (non-barrier and barrier methods) by WLH who do not wish to have a
child or further children could potentially have an important impact on reducing
unintended pregnancies, maternal morbidity and mortality in high risk WLH as well
as avert HIV infections in partners. Clearly interventions to address the gaps in
meeting women’s contraceptive needs are required both in the broader reproductive
health services and within HIV care settings.
In order to begin to address these gaps, it is necessary for health services to
understand not only the magnitude of this unmet need, but how it is distributed in the
population. In 2003, of the 5.2 million women globally who were married or regularly
cohabitating, 55.6% were currently using non-barrier contraception (NBC), and 15%
of this population alone had an unmet need for family planning (United Nations
Department of Economic and Social Affairs, 2007). In South Africa, 74% of the
general population of women using contraception used hormonal contraceptive
methods (either the progesterone-only injectable contraceptive or the oral
contraceptive pill) versus 4% condom use to avoid pregnancy (Rees, 2008).
However, there is very limited information on contraceptive use, and especially non-
barrier contraception use (NBCU), and knowledge of what factors contribute to
NBCU in HIV-positive women. Adding to our knowledge base in this area would not
only be beneficial for addressing inadequacies in current HIV and reproductive health
services, but also for creating national programmes to promote the use of NBC by
HIV-positive women to prevent unintended pregnancies.
1.2   Use of Different Methods of Contraception
1.2.1 Reasons for Use
Sexually active persons tend to use contraception for one or both of two reasons: to
prevent the transmission/acquisition of sexually transmitted infections (STIs) and
HIV/AIDS and to prevent unwanted pregnancy (Cates & Steiner, 2002).  Barrier
methods (male and female condoms) are the most effective forms of contraception for
preventing the transmission of infection, but are not the most effective forms of
contraception for preventing pregnancy, due to incorrect and inconsistent use












(sterilisation [male and female], oral contraceptive pills, progesterone-only injectable
contraceptives, implants, and intrauterine devices) are most effective at avoiding
pregnancy, but do not prevent infection. The use of contraception to prevent both STI
transmission and pregnancy is known as dual protection (Myer, et al, 2002). This can
either be in the form of use of barrier methods only to prevent both infection and
pregnancy, or dual method use when both barrier methods and a NBC method are
used concomitantly to achieve this same end.
Given the massive size of the HIV epidemic in South Africa and the endemic nature
of STIs, if sexually active clients choose to use only one method, health professionals
within HIV or STI care and treatment services, may primarily advocate use of
condoms to prevent STI infection, re-infection or further HIV transmission. On the
other hand, within sexual and reproductive health services that have had a historical
focus on pregnancy prevention, if health care providers are unaware of a client’s HIV
status, their primary focus may be on promoting a NBC method to prevent pregnancy
with condom- back up use until this is effective. Clients are likely to have diverse
needs with some who believe themselves to be in steady, monogamous relationships
perhaps being most concerned about an unintended pregnancy, while others who
engage in more casual sexual relationships may be more worried about contracting
STIs (Cates & Steiner, 2002).
1.2.2 Negotiating Contraception
In many developing countries, including South Africa, there is evidence that many
women in general feel uncomfortable “negotiating” contraceptive use with a male
partner (Santos, et al, 1998; Feldman & Maposhere, 2003; Delvaux & Nöstingler,
2007).  In a Argentinean study of people living with HIV, 37% of women claimed
that condom use was a “point of contention” with their sexual partner, and of the
women who did not report regular use of a condom, only 4.8% were attempting to
become pregnant (Gogna, et al, 2009).  However, recent findings suggest that if
family planning services were better integrated with HIV services this could facilitate
opportunities for young males to join their partners for the contraception consultation,
and South Africa may have a higher prevalence of condom and dual method use as a
result (MacPhail, et al, 2007). Sexual and reproductive health (SRH) services, apart












made it difficult to involve a general population of men in SRH services. Some men
may also disapprove of their female partners using a contraceptive method (Cooper, et
al, 2004) and women may, therefore, consider it important to have the opportunity to
use contraceptive methods that are not reliant on the male partner, but are controlled
by the woman herself.  Other than the female condom and the potential promise of
microbicides in the future, these women-controlled methods are mainly of the non-
barrier form. While they do not protect against infection unless used together with
barrier methods, they are very effective at preventing pregnancy if taken correctly
(Cates & Steiner, 2002). Hence, in the South African context there is a need among
all women, and especially HIV positive women, given the potential risks of
pregnancy if they are ill or wish to avoid having a child or further children, to achieve
better access to different forms of NBC, as well as barrier methods.
In South Africa, in particular, there is a lack of information and focus on the use of
non-barrier methods of contraception by HIV-positive women, as many of the
governmental policies for WLH have focused predominantly on the promotion of
barrier methods.   However, given the importance of WLH avoiding unwanted
pregnancies, it is vital that these women are given proper counselling on issues
surrounding the topic of NBC, while at the same time emphasising the importance of
barrier contraceptive use to avoid infection. This greater knowledge on the use of
NBC, in addition to barrier contraceptive methods, in HIV-positive women can aid
them in accessing contraceptive methods best suited to their individual needs.
1.3 Factors Associated with NBCU
1.3.1 Sociodemographic Factors
Like the general population, an HIV-positive woman’s need for contraception is
likely to change over the course of her life, which may suggest that NBCU may be
correlated with age (Magalhães, et al, 2002). In the general population of sexually
active South African women, contraceptive use (barrier and non-barrier) appears to be
inversely correlated with age, with those in the youngest group (15-19) having the
highest prevalence of contraceptive use (68.7%), with prevalence decreasing with
each subsequent age group (SADHS, 2007).  Studies from other countries have found












education (Allen, et al, 1993; Mitchell & Stephens, 2004). According to the 2003
South African and Demographic Health Survey (2007) of the general population of
South African women, there no longer appear to be a significant difference between
NBCU between urban and non-urban women, as the prevalence of NBCU in these
two settings is very similar (57.6% and 53.7%, respectively), due to increased use of
NBCU in rural areas.
1.3.2 Factors Associated with HIV Diagnosis that May Impact on Contraceptive
Use and Type of Method Used
Research from Brazil and a variety of other countries (Magalhães, et al, 2002;
Meursing & Sibindi, 1995; Smits, et al. 1999; Chen, et al. 2001; Nebie,et al, 2001;
Kirshenbaum et al. 2004)  suggests that an HIV-positive diagnosis can impact on both
women and men’s  sex lives.  Knowledge of a positive sero-status may cause the
woman to feel more reluctant to engage in sexual intercourse, resulting in reduced
sexual activity (Santos, et al, 1998).  However, as the women become more
comfortable with their sero-status and particularly if they become well again on
HAART, they may increase their sexual activity. This increases their need for both
barrier and non-barrier contraceptive methods, if they are to avoid infection and
unintentional pregnancies.  Research from another Brazilian study showed that
women’s use of different types of contraceptive methods changed in a statistically
significant way, following an HIV-positive diagnosis.  This study showed that
condom use, as well as tubal ligation, increased significantly (8.6% to 41.0%, and
9.5% to 26.6%, respectively), while use of the pill significantly decreased (40.0% to
6.7%) (Magalhães, et al, 2002).  This change is confirmed in an American study,
which found that after an HIV-positive diagnosis, women were less likely to use the
oral contraceptive pill and more likely to use male and female condoms, with 7%
using no contraception post-diagnosis, compared to 24% pre-diagnosis (p-
value=0.039) (Stanwood, et al, 2007).
1.3.3 Drug Interactions and Contraceptive Method Choice
Many of the NBC methods are hormonal in nature. Although more research is
necessary, it is suggested that the protease inhibitors and non-nucleoside reverse
transcriptase inhibitors found in some types of HAART, such as Nevirapine, interact












less effective in preventing pregnancy. This interaction seems to be particular to the
pill, as HAART does not appear to reduce the efficacy of the progesterone-only
injectable contraceptives, such as depot medroxyprogesterone acetate (DMPA) (the 3
monthly injectable) or norethisterone (the two monthly injectable) (El-Ibiary &
Cocohoba, 2008). Therefore, clinicians suggest that women who choose to use the pill
also use a barrier method so that both unwanted pregnancy and infection can be more
optimally prevented (Cejtin, 2003, Mitchell & Stephens, 2004). It may also be
possible to take a non-ritonavir boosted atazanavir or non-ritonavir boosted indinavir
to increase the contraceptive efficacy of the pill when taken with HAART (El-Ibiary
& Cocochoba, 2008).  Similarly, there is an interaction between the pill and the
tuberculosis (TB) drug Rifampicin, in which use of Rifampicin causes the pill to be
less effective (Cejtin, 2003; Mitchell & Stephens, 2004).  This is particularly
problematic in the South African context, as South Africa has a very high prevalence
(692 cases per 100,000 people) and incidence (948 cases per 100,000 people) of TB
with extremely high co-infection rates of HIV and TB. Of the 73% incident cases of
TB, half are HIV-positive (World Health Organisation, 2009). Hormonal oral
contraceptive may also be less effective if taken concomitantly with Rifabutin (used
for TB treatment), or antiretroviral drugs Ritonavir and Efavirenz (World Health
Organisation, 2008). Due to its possible reduced efficacy, HIV-positive women on
ART or Rifampicin may be advised not to use the pill or may themselves believe that
the method is not worth taking, and may therefore have a lower prevalence of use of
the pill as a NBC method than HIV-positive women who are TB-negative and not on
ART.
In the past, questions were raised about the possible complications of intra-uterine
device (IUD) use in HIV-positive women, such as an increased risk of acute pelvic
inflammatory disease (Cetjin, 2003; Mitchells & Stephens, 2004).  However, recent
evidence suggests that except for individuals with advanced HIV disease (World
Health Organisation stage III or IV), a history of bleeding disorders or a history of
pelvic inflammatory disease, use of the IUD is not only safe, but effective, for HIV-
positive women (Stringer, et al, 2007).  A recent study of HIV-positive women also
found that women who used an IUD were less likely to experience disease
progression than those taking hormonal contraception, such as the oral contraceptive












contraceptive methods, due to the past World Health Organisation recommendations
against its use by HIV-positive women, it is seldom promoted in this population of
women. This together with the lack of training in IUD insertion by medical
professionals in the public sector has led to a very low prevalence of IUD use
generally among South Africa women. Only 1% of women who are married or
regularly cohabitating are reported to use IUDS in the country (United Nations
Department of Economic and Social Affairs, 2007) and nearly all use occurs in the
private health sector.
1.3.4 Relationship Status
Evidence existing from a Rwanda study suggests that an association exists between a
WLH’s relationship status and her NBCU, as single women, compared to married
women, may be more likely to use certain NBC methods, such as injectables (Allen,
et al, 1993).  Another international study claims that the length of a woman’s
relationship does not appear to influence NBCU (Smits, et al, 1999). In terms of the
number of partners, a study from Uganda found that women with multiple sexual
partners were more likely to use hormonal contraception than women with one sexual
partner (Kiddugavu, et al, 2003).
1.3.5 Barrier Methods
Although dual protection is the ideal for HIV-positive women, as it helps to prevent
both STI and HIV/AIDS transmission and unwanted pregnancy, research strongly
suggests that adding a second method may be to the detriment of first method (Cates
& Steiner, 2002; Mitchell & Stephens, 2004), despite the fact that some women may
view condoms as a way of preventing the spread of disease rather than a contraceptive
method (MacPhail, et al, 2007).  While one study of 1232 WLH in the United States
showed that women using more permanent or effective forms of contraceptive
methods such tubal ligation [OR 17.2, 95% CI 1.28-2.33] or oral contraception [OR
1.44, 95% CI 1.00-2.08]), were less likely to use condoms than women not using
these contraception methods (Diaz, et al, 1999), it is not known whether the finding












1.3.6 Family Size and Fertility Intentions
Research from a study of HIV-positive women in Brazil suggested that the prevalence
of the type of NBC used by women is associated with the number of living children
they had.  Women with two or more children had a much higher prevalence of using a
permanent method to prevent pregnancy, such as tubal ligation, than women with no
children (89%, vs. 0%). Women who had one child had a higher prevalence of use of
hormonal methods (52% vs. 24%) than women without any children (Magalhães, et
al, 2002). A woman’s fertility intentions would be expected logically to influence
whether contraception is used and the type of contraception used (i.e. barrier or non-
barrier) in terms of its perceived effectiveness in preventing pregnancy, particularly in
an HIV-positive context.
1.3.7 Access to NBCU
Researchers from a Rwandan study concluded that the low prevalence of hormonal
contraception in the country may be due to women’s inability to access contraception,
as nearly 50 percent of women who did not use such contraception said they would
use hormonal injectable contraceptives, if it was made available to them (Allen, et al,
2003).  While access to contraceptives in South Africa is likely to be better, there is
scant information on contraceptive method availability and access issues that may
affect WLH, in particular. Issues of accessibility, as well as affordability (of the
contraceptive itself in countries where women pay for their contraception or travelling
to access it, as in the case of South Africa, where public sector provision of
contraception is free), have been raised by researchers, as possible barriers to NBCU,
as by their nature use of the most commonly used NBC methods require regular
interaction with health services (Delvaux & Nöstlinger, 2007M; Mitchell & Stephens,
2004).
1.4 Limitations of Existing Studies
Little research exists on the factors that affect NBCU in HIV-positive women,
particularly in a South African context.  Hence the proposed study will add to the
currently very limited knowledge.  Several studies on the topic have been conducted
in different countries such as Brazil, Rwanda, and the United States (Magalhães, et al,












these findings to South Africa, due to contextual issues (i.e. high prevalence of tubal
ligation in Brazil compared to South Africa and social differences) (United Nations
Department of Economic and Social Affairs, 2007). There is general consensus
internationally that more research on this topic in a diversity of contexts is needed
(Allen, et al, 1993; Lindsay, et al, 1995; Delvaux & Nöstlinger, 2007).
Many of the studies under review only focus on one aspect of the factors affecting
NBCU in HIV-positive women, such as pregnancy in HIV-positive women compared
to HIV-negative women, fertility in HIV-positive women, and broader attitudes
towards contraceptive use in HIV-positive women, thus giving an incomplete or
inaccurate portrayal of unmet need for contraception, factors influencing non-use and
the types of methods used (Lindsay, et al, 1995; Thackway, et al, 1997; Cejtin, 2003).
The proposed analysis in this paper will encompass a wider variety of factors that
may be related to NBCU in HIV-positive women in Cape Town, South Africa, than is
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Objective This study aimed to determine the prevalence of contraceptive use, and in
particular non-barrier contraceptive use (NBCU), in non-pregnant, HIV-positive
women, as well as the factors influencing the choice of NBCU.
Methods This sub-study comprised part of a large cross-sectional study that explored
fertility intentions and reproductive decision making of HIV –positive persons
attending public sector HIV care in a study in a suburb of metropolitan Cape Town.
Results Prevalence of NBCU was 66%, with 18% of women having a potential unmet
need for non-barrier contraception (NBC). Non-NBCU was inversely associated with
use of antiretroviral therapy (ART) (OR: 0.21 95% CI [0.10-0.44]), and positively
associated with having 0 or 1 living children compared to having 2 or more living
children (OR: 4.30 95% CI [1.41-13.15], OR:3.36 95% CI [1.44-7.81], respectively),
and age (OR: 1.06, 95% CI [1.00-1.16]). For different sub-groups of the study
population, non-NBCU appears inversely associated with being employed (OR: 0.17
95% CI [0.04-0.72]) and having one or more sexual partners in the past 6 months
(OR: 0.22, 95% CI [0.06-0.88]).
Discussion Although prevalence of NBCU among this study population of HIV-
positive women is higher than that of the general population of women, there is still a
potential unmet need for NBC among participants. Dual method protection needs to
be emphasized to avoid unintended pregnancy, as it can have especially dire
consequences for HIV-positive women. Those not currently taking ART may benefit
from a greater interaction with HIV-services, as this service may increase knowledge
and awareness of NBC.













South Africa has one of the largest populations of HIV-infected persons in the world,
at an estimated 5.7 million people [1].  The vast majority of those who are HIV-
positive are in their reproductive years, with a disproportionate number of females
being infected [1], and an estimated 29.3% of pregnant women testing HIV positive
[2].  International
research shows that sero-positive women have a high rate of unplanned pregnancy
[3].  According to a study by Cooper, et al [4], 11% of women not on antiretroviral
therapy (ART) reported having become pregnant after being diagnosed HIV-positive,
all of which were unintentional, compared to 9% of women on ART that reported
becoming pregnant after HIV-diagnosis, of which only a third were unintentional.
While it is important for health services to address the issue of unintended pregnancy
in all women, there is a particular urgency to do this in the case of HIV-positive
women, given the risk of vertical transmission of HIV and the potential negative
effects on the health of the women. Local research found AIDS related causes are the
main cause of maternal death in South Africa [5], with a recent study finding that very
ill HIV –positive women were seven times more likely to die in childbirth than other
high risk pregnant women [6].
These findings add urgency to the issue of ensuring that women living with HIV
(WLWH) in South Africa are able to optimise access to contraception should they
wish to avoid pregnancy.  While barrier methods are most effective in preventing
transmission of infection, they are less effective for preventing pregnancy due to
incorrect and inconsistent use.  Contrastingly, non-barrier contraception (NBC) is
most effective at avoiding pregnancy but does not prevent infection.  Therefore,
especially amongst WLWH, health professionals should advocate dual method
protection – the use of both a barrier method to prevent transmission of infection and
a non-barrier method to maximise protection against an unwanted pregnancy [7].
Despite evidence of the high prevalence of HIV/AIDS and unplanned pregnancy in
South Africa, there is very limited information on contraceptive use, and especially
non-barrier contraceptive use (NBCU), and knowledge of what factors contribute to
NBCU in HIV-positive women.  It is difficult to extrapolate findings from












While it is critical to emphasise condom use, information on NBCU is needed in order
to afford women the opportunity to choose to have maximum dual method protection
to prevent both infection and unwanted pregnancy.  Adding to our knowledge base in
this area would not only be beneficial for addressing inadequacies in current HIV and
reproductive health services, but also for creating national programmes to promote the
use of NBC and dual method protection by HIV-positive women to prevent
unintended pregnancies.  In this article we examine prevalence of NBCU and the
types of methods used in a group of HIV-positive women attending public sector HIV
care (pre and post – ART) in a Cape Town, suburb as well as factors influencing non-
use of NBC and this population’s potential unmet need for NBC.
2.3 Methods
This sub-study formed part of a larger cross-sectional study by Cooper, et al [11], that
examined fertility intentions, contraceptive service needs and reproductive decision
making among a representative sample of HIV-positive persons attending HIV care in
a high HIV-prevalence suburb in Cape Town, South Africa.  The interviews were
conducted from May to September 2006 at two public sector health care centres
providing voluntary counseling and testing (VCT) for HIV, general HIV care
services, ART services and a prevention of mother-to-child transmission of HIV
(pMTCT) for women testing HIV positive during pregnancy.
2.3.1 Sampling and Data Collection
A survey was conducted in which interviewers administered standardized structured
questionnaires with pre-coded answers, in face-to-face interviews. Interviews were
conducted in the subjects’ mother tongue and lasted approximately 30 minutes.
Individuals were selected to participate at random by researchers using random
number sequences and registers of patients attending each service that day. The
survey included questions pertaining to demographic and socioeconomic
characteristics, partnership status and sexual activity, HIV-infection and ART, use of
and access to contraceptive and reproductive health services, and fertility intentions.
The questionnaire asked women about their contraceptive use before and after HIV-













The final sample size of the study was 459 people, with an 88% response rate
amongst females and 90% amongst males.  As this analysis is concerned with
contraceptive use in HIV-positive women, all men (157 subjects) were dropped from
analysis.  Pregnant women (122) were also excluded, as they were believed to have
different contraceptive needs than non-pregnant women, leaving 180 women for
analysis in this report.
2.3.2 Statistical Analysis
All survey data was captured in a Microsoft Access 2000 customised template and
transferred to STATA Release 10 (STATACorp, College Station, USA), where all
subsequent analysis was performed.  NBCU was divided into three categories, as
outlined in the questionnaire: Before (use before HIV-positive diagnosis), After (use
following HIV-positive diagnosis), and Current (use currently).  Tabulated statistics
were calculated to compute the study population’s NBCU prevalence, as well as its
current potential unmet need for NBC.  To assess if there was a significant difference
in the study variables between non-users and users of NBC, a Chi-square, Wilcoxon
or Fisher’s Exact test was performed on each variable. To assess which factors
influence a WLWH to not currently use NBC, we constructed a series of logistic
regression models.  Separate models were built for the study population as a whole
(all 180 subjects) and for each of the sub-groups we examined (women using ART,
women not using ART, women with future fertility intentions, women without future
fertility intentions).  When building each model, we started with an empty model, and
each variable was tested separately for a crude analysis. From this, variables were
added one at a time and assessed on their significance (according to Akaikis
information criterion, likelihood ratio test, log likelihood, and chi-square). Lastly, as a
comparison, a full model (all variables) was constructed. McNemar’s Test was used
to determine if NBCU changed before and after HIV diagnosis.  A non-user of NBC
was defined as a study subject who stated she did not use one or more of the listed
NBC methods (oral contraceptive pill, the 2-monthly or 3-monthly progesterone-only
injectable contraceptive [hereafter referred to at the 2-monthly or 3-monthly
injectable contraceptive], intrauterine device, female sterilisation, male sterilisation).
A woman with unmet contraceptive needs was defined as a women who did not have












partners in the past 6 months) and who was not currently taking NBC.  All statistical
analyses were performed with STATA Release 10
2.3.3 Ethical Considerations
Ethical approval for larger study, of which this study comprise a sub-study, was
granted by the Ethical Review Committee of the World Health Organisation and the
Research Ethics Committee of the University of Cape Town, the research partners in
this study. All participants who agreed to the voluntary interview provided written
informed consent and were allowed to withdraw at any point during the study.
Although the risk of personal harm was very low, efforts were made to minimise non-
maleficence by having same sex interviewers who were trained in research
techniques, research sensitivity, and sexual and reproductive health, and the
administering of questionnaires occurring in private rooms to make the participant
more comfortable and able to provide honest answers.  Researchers referred those
experiencing emotional distress to appropriate counselling
2.4 Results
The median age of the women surveyed was 31 years (with a range of 18 to 55 years),
the median level education (schooling) completed was 10 years, and the median
number of years since being diagnosed as HIV-positive was 3 years. The majority of
participants were unemployed (82%); had a household income of R1000 or more per
month (61%); had one or more sexual partners in the past 6 months (75%); were
currently using ART (58%) and believed it was easy to access contraception (95%).
While a significant minority (45%) were open to the possibility of having a child in
the future, the majority reported not wishing to have any children in future (55%).  In
addition, 16% of women had no living children, 42% had one living child and a
further 42% had two or more living children. A minority of women (27%) reported
not being in a current sexual relationship (Table 1).
As can be seen in Table 1, in a bi-variate analysis, there was a statistically significant
relationship (p-value <0.05) between NBCU, median level of education, median time
since diagnosis, use of ART, and perceived difficulty in accessing contraception.
However, perceived difficulty in accessing contraception was dropped from any












respondents of that question reported that they believed it easy to access
contraception, with only 4 women reporting they believed it difficult to access (Table
1).
As shown in Table 2, 158 women (88%) reported ever use of NBC, before having
been diagnosed with HIV. The most commonly used methods before diagnosis were
the 2- and 3- monthly injectable contraceptive (53% and 52%, respectively) and the
oral contraceptive pill (15%). Nine (5%) of the 180 women in the study reported
being sterilised before being diagnosed HIV-positive. Twenty-two women (12%)
were using dual method protection and 21 (12%) were not using any form of
contraception. Use of NBC was reported by 122 women (68%) after diagnosis with
HIV, with a large increase in dual method use and condom use (39% and 56%,
respectively).  At the time of the study 118 women (66%) reported current use of
NBC, with 68 (26%) using dual method protection, 13 (7%)  using condoms only, and
29 (16%) not using any form of contraception or infection protection.  For current
users of NBC, the 3-month injectable contraceptive was by far the most widely used
form of contraceptive method, with 42% of the study population currently using it.
Other forms of contraceptives currently used by study subjects included oral
contraceptive pill (1%), two-month injectable (16%), female sterilisation (8%),
female condom (1%) and male condom (44%).
An HIV-positive diagnosis has a significant effect on the decision not to use NBCU
(p-value <0.0001).  Non-users of NBC before diagnosis were 0.23-fold (95%
Confidence Interval [CI] 0.11-0.46) as likely to use NBC after diagnosis and 0.27-fold
(95% CI 0.14-0.49) as likely to currently be using NBC as women using NBC before
diagnosis. However, there was not a significant change in non-use of NBC from the
time following diagnosis to current use  (time of study participation) (Appendix E.3).
Additionally, according to our calculations, there were currently 32 women (18%)
with a potential unmet need for NBC (Table 2).
Table 4 shows the model building process for a logistic regression analysis of all 180
women.  The final model (Model 2) shows a highly significant inverse association












[0.10-0.44]), with non-use of ART making it more likely that a woman would not
currently be using NBC.  This model also shows an association between non-use of
NBC and women having a lower number of living children.  Women with no living
children were 4.30-fold (95% CI [1.41-13.15]) more likely to be non-users of NBC
than women with 2 or more living children, as were women with one living child,
who were 3.36-fold (95% CI [1.44-7.81]) more likely to be non-users of NBC than
women with 2 or more living children.  There was no significant association found
between NBCU and having no vs. 1 child in any of the models.  Age also proved to
be significantly associated with non-use of NBC, with women being 6% (OR: 1.06
95% CI [1.00-1.12]) less likely to be currently be non-users of NBC for every year
over the age of 20 (baseline age).  No other significate relationships were found
between non-NBCU and any of the other variables (Table 4, Model 2).
For those without future fertility intentions (n=171) (Table 5, Model 3), an
association between non-NBCU and ART use (OR: 0.20 95% CI [0.08-0.50]),
number of living children (0 vs. 2+ OR:4.32 95% CI [1.07-17.47], 1 vs. 2+ OR: 3.56
95% CI [1.29-9.82]), and age (OR: 1.10 95% CI [1.03-1.18] still exists, but the
strength of the relationships between non-use of NBC and number of living children
and non-use of NBC and age are slightly stronger..  There is also an additional
significant inverse association (Table 5, Model 3) between being employed
(compared to being unemployed) (OR: 0.17, 95% CI [0.04-0.72] and non-use of
NBC.  For those not currently using ART, there was a significant inverse association
between non-NBCU and having one or more sexual partners in the past 6 months
(compared to not having any sexual partners) (OR: 0.22 95% CI [0.06-0.88])
(Appendix E.8, Crude Models).
2.5 Discussion
With a current NBCU prevalence of 67.8% and a before diagnosis ever-use
prevalence of 88%, this sample of HIV-positive women utilising public sector HIV-
care facilities in Gugulethu appears to have a higher current NBC prevalence than the
general South African population.  Among the general population of South Africa
women, modern NBC prevalence is estimated at 43.9% amongst all women 15-49,
and 56.4% amongst those having sexual intercourse in the past 4 weeks, while ever-












[12].  While these results are encouraging, as the population in this study has a special
need for NBC, there is still room for improvement.  We estimate that 18% of the
population may have an unmet need for NBC, as these women are not currently
taking NBC, are sexually active (have had one or more sexual partners in the past 6
months) and did not have any immediate intentions to become pregnant. Although
difficult to compare due to different fertility intentions and potential health risks in the
two groups, the unmet need for NBC in this sample of HIV-positive women is greater
than the unmet need for family planning services (13.8%) in the general population of
South African women [12]. The decline in the use of oral contraceptives (15% to 1%)
and increase in male condom usage (13% to 56%) from ever use before and after
HIV-diagnosis agrees with a recent American study, which found that after an HIV-
positive diagnosis, women were less likely to use the oral contraceptive pill and more
likely to use male and female condoms, with 7% using no contraception post-
diagnosis, compared to 24% pre-diagnosis (p-value=0.039) [13].
The results from this study suggest that the factor that most strongly influences a
woman’s decision not to use NBC is her use of ART (OR: 0.21 95% CI [0.10-0.44]).
Perhaps women not currently using ART are less likely to be users of NBC than
women using ART because the women using ART have more interaction with HIV
services, and therefore, may receive more education about the importance of NBC as
a method of preventing unwanted pregnancy
The finding that shows that women with no children or few children (<2) were more
likely to be non-users of NBC, suggests that these women may not be using NBC
because they may wish to increase their family size and, conversely, that women with
2 or more children may be using NBC as they do not want to have any more children.
Women with 2 or more children may wish to limit their family size due to financial
constraints or to protect their health from any hardships that may be incurred from an
additional pregnancy due to their HIV-positive status.
Our results show that for every year over 20 years of age, a woman is 6% more likely












For the sub-group of those without fertility intentions, the associations from the model
of All Subjects (inverse association between non-NBCU and use of ART, positive
association between non-NBCU and number of living children, age) found in Table 4
Model 2 persisted.  In addition, being employed was found to be significantly and
inversely related (OR: 0.17 95% CI [0.04-0.72) to non-use of NBC (Table 5, Model
3). Although the reasons for the NBC use in relation to employment status were not
probed in this study, women who are unemployed may be less likely to be users of
NBC, due to the possible financial constraints of accessing NBC (transport costs, etc).
Having one or more sexual partners in the past 6 months was also significantly
inversely associated with non-NBC use in women who were not currently using ART
(OR: 0.22 95% CI [0.06-0.88]). This is a logical finding, as it shows that women
without a recent sexual partner are more likely to be non-users of NBC, compared to
women who have recently been sexually active.
The findings of the study also show that an HIV-positive diagnosis influences a
woman’s ever use of NBC in a statistically significant way.  Of the 58 (32%) women
who changed NBCU after diagnosis, 11 (6%) began NBCU, while 47 (26%)
discontinued NBCU (Table 2). The majority of those who discontinued use may have
done so in favour of solely using a barrier method, as there was only a slight increase
in those not using any method of contraception. Although use of dual protection
increased after diagnosis, ideally all sexually active women who wish to avoid
pregnancy should utilise this method, as it is the ideal for HIV-positive women, as it
helps to prevent both STI and HIV/AIDS transmission and unwanted pregnancy [7].
This study has several limitations. As this study is cross-sectional, associations can be
formed but no causality can be assessed.  In addition, there is likely a degree of recall
bias present in the results, as participants were required to answer questions pertaining
to the period before HIV-diagnosis and immediately after, with this being a period of
up to 9 years for some participants.  This study also has a relatively small sample size
(180), with some sub-groups of analysis having as few as 20 subjects.  Especially
among the sub-groups, we may have found that several other variables could have












Despite the study’s limitations, the findings add to our knowledge base on NBC use
and could be beneficial for addressing inadequacies in contraceptive service provision
for HIV-positive women in this setting. Although 26 percent of HIV-positive women
reported currently using dual method contraception to protect themselves from
unwanted pregnancy and disease transmission, according to our calculations, there is
still a considerable proportion of unmet need (without current fertility intentions,
sexually active) for dual use for this population (33%). Governmental policy and
health care providers should be encouraged to work together to ensure awareness,
knowledge, and access to both barrier and non-barrier methods of contraception.
While it is of paramount importance to avoid STI’s and further transmission among
HIV positive individuals, increased efforts are needed in more effectively promoting
additional use of NBCU among HIV positive women. This could decrease unwanted
pregnancies, which have especially dire consequences for HIV-positive women, as
they may compromise the health of an unwell HIV-positive woman and lead to
vertical transmission. Findings from this study also highlight the need for special
attention to be given to promotion of NBC among HIV-positive women not currently

































2 3 3 0.001*^
0 14 (48) 15 (52) 29 (16)
1 29 (38) 47 (62) 76 (42)
NUMBER OF LIVING
CHILDREN (n=180)
2+ 19 (25) 56 (75) 75 (42)
0.058**
Unemployed 53 (36) 93 (64) 146 (82)EMPLOYMENT
STATUS
 (n=179)
Employed 9 (27) 24 (73) 33 (18)
0.325**
<R1000 25 (35) 46 (65) 71 (39)HOUSEHOLD INCOME
PER MONTH (n=180) R1000+ 37 (34) 72 (66) 109 (61)
0.861**
0 19 (42) 26 (58) 45 (25)NUMBER OF SEXUAL
PARTNERS IN PAST 6
MONTHS (n=180)
1+ 43 (32) 92 (68) 135 (75)
0.205**
Not on ART 37 (51) 35 (49) 72 (42)ART (n=171)
On ART 21 (21) 78 (79) 99 (58)
<0.000**^
No 7 (32) 15 (68) 22 (12)NBCU BEFORE
DIAGNOSIS (n=180) Yes 55 (35) 103 (65) 158(88)
0.782**
Easy 27 (21) 103 (79) 130 (95)








3 (100) 0 3 (2)
0.011***^
No 29 (37) 50 (63) 79 (44)CONDOM USE AFTER
DIAGNOSIS (n=180) Yes 33 (33) 68 (67) 101 (56)
0.572**
Not in a Sexual
Relationship
18 (38) 29 (62) 47 (27)






23 (32) 50 (68) 73 (41)
0.762**
Right Now 4 (36) 7 (64) 11 (6)
In Next 12 Months 3 (33) 6 (67) 9 (5)
May Sometime in
Future
10 (36) 18 (64) 28 (16)
Do Not Want a
Child





9 (27) 24 (73) 33 (18)
0.916**
*-Wilcoxon Rank-Sum Test, **-Chi-square Test, ***Fisher’s Exact Test













Prevalence of methods of non-barrier and barrier contraceptive use (ever use) before HIV+ diagnosis, after
diagnosis, and current use
Method Ever Use (%) (median
time 13 years)
After  (%) (median
time 3 years)
Current (%)










93 (52) 75 (42) 75 (42)
IUD 3 (2) 0 0
Female sterilisation 9 (5) 13 (7) 14 (8)
Male sterilisation 0 0 0
Female condom 0 2 (1)* 1 (1)
Male condom 23 (13) 100 (56)* 80 (44)
Diaphragm 0 0 0
Other 0 1 (1) 0
No method used 21 (12) 26 (14) 29 (16)
Dual method 22 (12) 71 (39) 68 (26)
Any NBC method 158 (88) 122 (68) 118 (66)
*One user of the female condom also used male condoms
Table 3
Potential unmet non-barrier contraceptive need
Fertility Intentions No Current NBCU (-) Current NBCU (+)
Sexually active & would like child
within 12 months (A)
7 (5%) 13 (10%)
Sexually active & would like child
sometime in future (B)
8 (6%) 16 (12%)
Sexually active & does not want
child in the future (C)
22 (16%) 44 (33%)
Sexually active & unsure of fertility
intentions (D)
6 (4%) 19 (14%)
Not sexually active & would like
child within 12 months (E)
0 0
Not sexually active & would like
child sometime in future (F)
2 (4%) 2 (4%)
Not sexually active & does not want
child in the future (G)
14 (31%) 19 (42%)
Not sexually active & unsure of
fertility intentions (H)
3 (7%) 5 (11%)
(A-D)-% out of all sexually active women (135)












Table 4: Logistic regression model building process for non-use of NBC by all subjects





1.02 (0.98-1.06) 1.06 (1.00-1.12)^ 1.07 (1.00-1.14)^
Education (per
year, baseline = 2
years)
0.88 (0.76-1.02) 0.87 (0.71-1.07)
Years Since
Diagnosis (per
year, baseline = 0
years)
0.79 (0.69-0.92)^ 0.90 (0.75-1.07)
Living Children*
    0 Children
















0.95 (0.50-1.77) 1.10 (0.49-2.48)
Sexual Partners in
Past 6 Months (1+
vs. 0)
0.64 (0.32-1.28) 0.53 (0.16-1.71)
Use of ART 0.25 (0.13-0.50)^ 0.23 (0.11– 0.45)^ 0.21 (0.10-0.44)^ 0.22 (0.09-0.52)^
NBCU Before
Diagnosis
1.14 (0.44-2.97) 0.89 (0.28-2.77)
Condom Use After
Diagnosis

















*-In comparison to having 2+ living children
**-In comparison to not being in a sexual relationship
***-In comparison to not having any future fertility intentions











Table 5:Logistic regression model building process for non-use of NBC by women without fertility intentions












1.03 (0.98-1.09) 1.06 (1.0-1.12)^ 1.10 (1.03-1.18)^ 1.10 (1.02-1.19)^
Education (per
year, baseline = 2
years)
0.86 (0.72-1.04) 0.96 (0.75-1.23)
Years Since
Diagnosis (per
year, baseline = 0
years)
0.79 (0.66-0.93)^ 0.91 (0.74-1.13)
Living Children*
    0 Children















0.73 (0.35-1.52) 1.09 (0.42-2.86)
Sexual Partners
in Past 6 Months
(1+ vs. 0)
0.63 (0.29-1.34) 0.46 (0.12-1.85)
Use of ART 0.28 (0.13-0.61)^ 0.25 (0.11-0.57)^ 0.23 (0.10-0.53)^ 0.20 (0.08-0.50)^ 0.19 (0.06-0.56)^
NBCU Before
Diagnosis
1.33 (0.39-4.51) 1.24 (0.26-5.9)
Condom Use
After Diagnosis









*-In comparison to having 0 living children
**-In comparison to not being in a sexual relationship
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Informed consent for quantitative interviews with HIV women and men (VCT,
pMTCT and HIV care participants)
Hello, my name is……………….. I work at the University of Cape Town's Women's
Health Research Unit. We are talking to HIV positive people from health care facilities
around Cape Town. We want to better understand people’s attitudes and concerns about
having children, and other things having to do with their reproductive health, as well as
their experiences with the health care services.  We hope that this information will be used
to improve health care services for people living with HIV/AIDS.
As someone affected by HIV, we would like to invite you to participate in this study.  We
think that your experiences can contribute to understanding these issues. We would like
to find out about your thoughts and attitudes regarding HIV positive people’s
childbearing, use of contraception, and access to related health services. This includes
your personal experiences of the health care services, and how you think the services may
be improved.
Right to refuse or withdraw
You do not have to take part in this research if you do not wish to do so, and refusing to
participate will not affect your current or future treatment at the health facility here in any
way. You will still have all the benefits that you would otherwise have at this health
facility.  You may stop participating in the interview at any time that you wish without
losing any of your rights as a patient here. If you do not wish to answer any of the
questions included in the survey, you may skip them and move on to the next question.
The
Procedures
If you agree to participate, we will ask you to sign a consent form I will also ask you a
series of short questions. I will write down your answers so that we know what you have
said, but we will not record your name on the questionnaire or anything that could be
used to identify you. The expected duration of the entire process will be about 30
minutes.
Confidentiality
The interview will take place in a room in the clinic and no one else but the interviewer
will be present. The information recorded is considered confidential, and no one else
except our research team will have access to the completed questionnaire. The number
assigned to each file will be kept under lock and key and will not be divulged to anyone.
The consent form will be kept separately from the questionnaire.
Risks and Discomforts:
Your participation in this study will not involve any risks to you.There is a slight risk that
you may share some personal or confidential information by chance or that you may feel
uncomfortable about talking about some of the topics. However, you may refuse to
answer any question or not take part in a portion of the questionnaire if you feel the













There will be no direct benefit to you, but your participation is likely to help us find out
more about HIV positive people’s reproductive health choices and service needs.  You
will not be provided any incentive to take part in the research. However, you will be
reimbursed with R20 for your time and travel expenses.
Who to contact:
If you have any questions you may ask those now or later. If there is anything that is
unclear or you need further information; we shall be pleased to provide it. [Interviewer
ask if the respondent has any questions and provide the necessary clarification]. If you
wish to ask questions later, you may contact any of the following: Dr Di Cooper,
Women’s Health Research Unit, Tel: 406-6528; email: dic@cormack.uct.ac.za or Ms
Sheila Cishe; Tel: Women’s Health Research Unit, Tel: 406-6819
This proposal has been reviewed and approved by the University of Cape Town’s
Research Ethics Committee, whose task it is to make sure that research participants are
protected from harm. If you wish to find about more about the Committee, contact
Professor T Zabow, E46 Room 26, Old Main Building Groote Schuur Hospital; Tel: 021-












Certificate of Consent for Quantitative Study
I have been invited to take part in the research on the health of HIV positive people,
specifically their decisions to have children, or to use contraception, and health services
related to these things.  I have read the foregoing information, or it has been read to me. I
have had the opportunity to ask questions about it and any questions I have been asked
have been answered to my satisfaction. I consent voluntarily to be a participant in this
study and understand that I have the right to withdraw from the interview at any time
without in any way affecting my medical care.
Print Name of Subject 
____________________________





Print Name of Independent Literate Witness. (If possible, this person should be selected
by the participant and should have no connection to the research team.)
____________________________




Print Name of Researcher
____________________________














Questionnaire for quantitative interviews with HIV infected women & men (update end May
2006)
IMPORTANT: ENROL ANYONE ELIGIBLE: ONLY DON’T INTERVIEW PERSON AT 1ST VISIT IF THEY
OR THE PROVIDER FEEL THEY ARE NOT READY TO BE INTERVIEWED. For all questions with pre-
coded options except for yes or no, unless otherwise stated, wait for participant’s response and then
read pre-coded list and check with them which one to circle.
# Item Coding Skip
NOTE: INTERVIEWER TO COMPLETE A –D BEFORE OR AFTER INTERVIEW
A Participant ID number (Use folder number)
B Facility name
C Date of interview DD/MM/YYYY
D Participant source
(Do not read: Interviewer to complete)
pMTCT=1
VCT=2
HIV care (non –ART) =3




F INTERVIEWER: Does the participant meet all study eligibility criteria Yes=1  /   No=0
G INTERVIEWER: Has the participant completed the IC process? Yes=1  /   No=0
Demographic & socioeconomic characteristics




 How old are you?
[Buyintoni ubudala bakho?]
Age in years





If _1 to 4,
otherwise skip
to 5
 What work do you do?
[Wenza hlobo luni lomsebenzi?]
Specify: __________
 What is your home language?





Other=5  specify: __________
 What is the highest level of schooling/education that you have completed?




 What kind of home do you live in?






 Including yourself, how many people live in your household?
[Xa uzibala nawe, bangaphi abantu abahlala ekhayeni lakho?]
Number of people
 What is the approximate income for your household, per month?
[Xa uqikelela ungathi ingakanani ingeniso yemali endlini ngenyanga?]
No household income=0
R 1-500 / month = 1
R 501-999 / month = 2
R 1000-1999 / month = 3
R 2000-2999 / month = 4
R 3000-4999 / month = 5
R 5000-7999 / month = 6
R 8000 / month or greater = 7
Don’t Know =9
 Are you or your partner currently pregnant?












 If yes, how many boys and girls? (Do not read: Interviewer to complete)
[Ukuba kunjalo ngamakwenkewe  neentombi ezingaphi?]]
Males:
Females:
 How old is the youngest of your living children?
[Buyintoni ubudala boyena mntwana wakho  umncinane kwaba baphilayo?]
Age in years
 How many of your children are living with you now?













# Item Coding Skip
 Have any of your children died
[Ukhona umntwana wakho owaselwekayo?]
Yes = 1
No = 0
If no _ 17
 If yes, what did he/she die of
Ukuba ewe, wabulawa yintoni?]
1 = AIDS related cause
2 = Other
9 = Don’t know
 Are you taking care of any other children who are not your own?
[Bakhona abantwana abaphantsi kogcino lwakho abangengobakho? ]
Yes=1
No=0
Partnership status & sexual activity
Now I would like to ask you some questions about your sexual relationships and
past sexual activity
[Ngoku ndingathanda ukukubuza imibuzo emalunga nobuhlobo bokwabelana
ngesondo nangokwabelana ngesondo kwixesha elingaphambili]
 Are you currently in a sexual relationship?




 How would you describe this relationship? (Read list)
[Ungakuchaza njani ukuhlobana kwakho?]
Married=1
Not married, living together =2




 How long have you been in this relationship?
[Unethuba elingakanani uhlobana?]
Duration in years (use decimals
for months)
 Is this person the parent of any of your children?







 Approximately how many sexual partners have you had in the past 6 months?
]Xa uqikelela mangaphi amaqabane okwabelana ngesondo othe wanawo
kwezinyanga zintandathu zidlulileyo?]
Number of partners
 Approximately how many times have you had sexual intercourse in the last month
altogether (interviewer to summarise for all partners)?
[Xa uqikelela ungathi mangaphi amathuba usabelana ngesondo kule nyanga
idlulileyo?]




 When you last had sexual intercourse did you use a male or female condom?






 How frequently have you / your partner(s) used condoms during sexual
intercourse in the last 6 months? (interviewer to summarise for all partners)
(read list)
[Uphindaphinde kangakanani wena / iqabane lakho ukusebenzisa ikondom
ngethuba nisabelana ngesondo kwezinyanga zintandathu zidlulileyo?]
Always (in 100% of the time)=1
Most times (> half of the time)=2
Some times (about half of the
time)=3
Rarely (< half of the time)=4




HIV infection / antiretroviral therapy
Now, I would like to ask you some questions about when you found out you had
HIV
[Ngoku ndingathanda ukukubuza imibuzo malunga nethuba owafumanisa ngalo
ukuba usuleleke yiNtsholongwane ka Gawulayo]
 When did you find out that you were HIV-positive?
[Ufumanise nini ukuba usuleleke yintsholongwane kaGawulayo ?]
Enter year (4 digits): _______
Enter months ago: ______
 Where did you first find out that you were HIV-positive?
[Uyifumanise phi okokuqala ukuba usuleleke yintsholongwane kaGawulayo?]
Tested at ANC/PMTCT
service=1
Tested at TB/STI service=2
Tested at Hospital/other health
service=3
Partner referral = 4
Other=5 specify:__________
 Think about after finding out you were HIV-positive, how many new sexual
partners have you had since then?
[Mangaphi amaqabane amatsha othe wanawo ukususela ukufumanisa kwakho
ukuba usuleleke yintsholongwane kaGawulayo?]
Enter number
 Once again, thinking about after finding out you were HIV-positive, have you had
sexual intercourse more frequently, less frequently, or as frequently, compared to
before you knew you were HIV positive?
[Ukuphindaphinde ngaphezu kwesiqhelo, ngaphantsi kwesiqhelo okanye
ngokwesiqhelo ukwabelana ngasondo emva kokuba ufumanise ukuba usuleleke


















# Item Coding Skip
 After you found out that you were HIV-positive, have you/your main partner
become pregnant? If yes, how many times?
[Ingaba wena okanye iqabane lakho nikhe namitha emveni kokufumasa ukuba
usuleleke yintsholongwane kaGawulayo? Ukuba ewe, kangaphi?]
Enter number If no, or male
& no
partner_33
 For the last time you became pregnant, after you found out you were HIV-
positive, were you/your main partner trying to become pregnant at the time?










 Have you (or your main partner) ever been given medication at the clinic to
prevent the mother-to-child transmission (pMTCT) of HIV infection?
[Ingaba wena (okanye iqabane lakho) nakhe nanikwa amayeza ekliniki okuthintela
ukusulelwa komtwana ngumama (pMTCT) yintsholongwane kaGawulayo?]
[Interviewer: carefully distinguish antiretroviral drugs given for PMTCT from other
medications given to women during pregnancy]
NOTE: IF CURRENTLY PREGNANT INCLUDE THIS PREGNANCY
Yes=1
No=0
Don’t know/unsure = 9
 If male and
no partner
_35
 If yes, during how many pregnancies have you/ main your partner received
medication for this purpose?
[Ukuba ewe, kukumathuba amangaphi okumitha ufumana amayeza ngale
njongo?]
Number
 ANTIRETROVIRAL THERAPY: NOTE: IF PARTICIPANT IS NOT ON ARV’S
SKIP TO 42
Are you currently taking antiretroviral therapy (ART) for treating HIV infection?
[Uyalufumana unyango lwamachiza (ART) okunyanga usuleleko yi
ntsholongwane kaGawulayo]





 Approximately how long have you been taking ART?
[Xa uqikelela unethuba elingakanani uthatha iART]
Enter year (4 digits): _______
Enter months ago: ______
 Think about after starting to take ART, how many new sexual partners have you
had since then?
[Mangaphi amaqabane okwabelano ngesondo okhe wanawo ukususela kwakho
ukuthatha iART?]
Enter number
 Once again, think about after starting to take ART,  have you had sexual
intercourse more frequently, less frequently, or as frequently, compared to before
you started?
[Ukuphindaphine ngaphezu kwesiqhelo, ngaphantsi kwesiqhelo okanye





Not sexually active since finding
out HIV-positive=4
Don’t know/unsure=9
 After starting to take ART, have you/your main partner become pregnant? If yes,
how many times?
[Ingaba wena okanye iqabane lakho uikhe wamitha oko wathi waqala I-ART?
Ukuba ewe, kangaphi?]
Enter number If no, or if
male and no
partner _42
 For the last time you became pregnant after starting taking ART, were you/ main
your partner trying to become pregnant at the time?
[Ukugqibelo kwako oko ukwenzeka ingaba wena okanye iqabane lakho
beniluzama olomitho ngelo xesha? ]
Yes=1
No=0







Next, I would like to know more about your contraceptive use, or your partner’s
contraceptive use……..
[Ukolandelayo ndingathanda ukwazi malunga  nokucwangcisa kwakho okanye
ukucwangcisa kwe qabane lakho]
Think about before you found out you were HIV-positive, did you or your partner
use any of the following contraceptive methods? (Read all options, circle as
many as apply)
 [Ngaphambi kokuba ufamanise ukuba usuleleke yintsholongwane kaGawulayo




































# Item Coding Skip
 Think about after you found out you were HIV-positive, have you or your partner
used any of the following contraceptive methods? (Read all options, circle as
many as apply)
[Oko wathi wafumanisa ukuba usuleleke yintsholongwane kaGawulayo, ukhe

























 INTERVIEWER: SKIP IF PARTICIPANT IS NOT TAKING ART
Think about after you started to take ART, have you or your partner used any of
the following contraceptive methods? (Read all options, circle as many as
apply)
[Oko uthe waqalisa ukuthatha I-ART, ukhe wena okanye iqabane lakho
























 Think about now, currently, which of the following contraceptive methods are you
(or your partner) using? (Read all options, circle as many as apply)
[Ngoku, zeziphi iintlobo zokucwangcisa ozi (okanye iqabane lakho) sebenzisayo?]
NOTE: INTERVIEWER IF PARTICIPANT IS ALSO USING CONDOMS
RESTRICT THIS QUESTION TO METHODS OTHER THAN CONDOMS. IF
PARTICIPANT IS ONLY USING CONDOMS OR IS STERILISED GO STRAIGHT
























 Where do you/your main partner go (or where would you go) to access
contraception?
[Uyaphi / iqabane lakho (okanye ningayaphi ) ukuyakufumana ucwangciso?]
This health facility=1







 If you/your partner wanted contraception, how difficult or easy do you think it is for
you/your partner to access contraception? (read all options)
[Ukuba wena / iqabane lakho ufuna ucwangciso, ucinga kungalula kangakanani






 If you/your partner wanted contraception, could you receive contraception during
the same visit to this facility when you come to receive HIV-related care (ART or
other HIV-related care)?
[Ukuba wena / iqabane lakho ufuna ucwangciso, ungalufumana ucwangciso
ngaxesha nye undwendwele kule kliniki ngokuzokufumana uncedo olunxulumene





 Where do you/your partner go (or where would you go) to access condoms?
[Uyaphi wena / iqabane lakho (okanye ungayaphi) ukuyakufumana iikondom?]
This health facility=1







 If you/your partner wanted condoms, how difficult or easy do you think it is for
you/your partner to access condoms? (read all options)
[Ukuba wena / iqabane lakho ufuna iikondom, ucinga kungalula kangakanani

















# Item Coding Skip
 If you/your partner wanted condoms, could you receive condoms during the same
visit to this facility when you come to receive HIV-related care (ART or other HIV-
related care)?
[Ukuba wena / iqabane lakho ufuna iikomdom, ungazifumana iikondom ngaxesha
nye undwendwele kule kliniki ngokuzokufumana uncedo olunxulumene





Other reproductive health services
 Have you ever heard of a Pap smear?
[Wakhe weva nge Pap smear?]
Yes=1
No=0
If NO: A Pap smear is a test that a woman can have to check for any abnormal
cells in the mouth of the womb that could lead to cancer. For this, a nurse inserts
a speculum (spoon) into the vagina so that she can see the mouth of the womb
and uses a spatula to take the sample of cells.
[Ukuba HAYI: I-Pap smear luhlolo olungafunyanwa ngowasethyini ukukhangela
ukuba akukho zisele ezingaqhelekanga emlonyeni wesibeleko ezinokuthi
zikhokhelele kwisifo somhlaza. Ukwenza oku, umongikazi ufaka icepe kwisini
ukwenzela abone umlomo wesibeleko aze asebenzise i-spatula ukuthatha
isiqingatha sezozisele. ]
IF male  _ 55
 Have you ever had a Pap smear?





 If yes, when was your last Pap smear?
[Ukuba ewe, wagqibela nini ukwenza iPap smear?]
Enter year: _________
Code for timing of last Pap
smear: Before found out
HIV-   positive= 1; Since
found out was HIV-
positive= 2;  Since starting
ART= 3; Unsure=9
 Have you ever heard of emergency contraception?




If NO: If NO: Emergency contraception are pills that a women can take up to 96
hours after having unprotected sex to help prevent pregnancy. It works
best up to 72 after unprotected sex.  It is also called the ‘morning
after’ pill.
[Ukuba HAYI: Ucwangciso olukhawulezileyo (EC) lichiza elifumaneka
kwabasetyhini kumyinge we yure iziyi96 emva kokuba eye wabelana ngesondo
engazikhuselanga ukunqanda umitho. Isebenza ngokugqibeleleyo kumyinge we
yure eziyi72 emva kokwabelana ngesondo ungasikhuselanga. Iya ibizwe
nangokuba yi “morning after pill”.]
 If the participant now recognizes emergency contraception (by its definition),
circle “recognizes EC”
Recognizes EC=1
 Think about after you found out you were HIV-positive, have you (or a partner)
used emergency contraception?
[Wakhe wena (okanye iqabane lakho) walusebenzisa ucwangiso





If no_ or IF
male &  no
partner _58
 Think about after you started ART, have you (or a partner) used emergency
contraception?
[Wakhe wena (okanye iqabane lakho) walusebenzisa ucwangciso
olukhawulezileyo oko wathi waqala I-ART?]
Yes=1
No=0




GIVE THIS EXPLANATION: Termination of pregnancy (TOP) (abortion) is legal
and available to women at certain public health facilities in South Africa. The law
allows an abortion/TOP to be accessed by any woman until up to 12 weeks of
pregnancy, and for specific reasons up to 20 weeks of pregnancy.
[Ukunqamla ukumitha (TOP) (ukuqhomfa) kusemthethweni futhi kuvelelekile
kwabasethyini kwindawo zonyango loluntu ezithile apha Emzantsi Afrika.
Umthetho uvumela ukuba ukuqhomfa / unqamlo mitho lufumanake kuye nawuphi
na owasethyini okumyinge weveki eziyi12 zokumitha, kwimiba ethile uyakuma
kwiveki eziyi20 zomitho].
 Did you know that it is possible for a woman to have a legal abortion/TOP?




 Think about after you found out you were HIV-positive, have you (or a partner)
had an abortion/TOP?
[Cinga emva kokuba ufumanise wafumanisa ukuba usuleleke yintsholongwane




Don’t know = 9














# Item Coding Skip
 If yes, can you give the reason why that pregnancy was terminated
[Ukuba ewe, ungasinika isizathu sokuqhomfa esosisu?]
Related to HIV-status = 1
Unrelated to HIV- status = 2
Don’t know = 9
 Was this abortion/TOP provided at a health facility?
[Ingaba okukuqhomfa/ olunqamlo mitho lwalwenziwe kwindawo yezempilo]
Yes:, at a public clinic/
hospital=1
at a private clinic or hospital=2
No, not provided at a health
facility =3; Don’t know=9
 Think about after finding out that you are HIV-positive, have you or your partner
ever felt pressurized by a health care provider to have a termination of
pregnancy?
[Cinga emva kokufumanisa kwakho ukuba usuleleke yintsholongwane ka
Gawulayo, ukhe wena okanye iqabane lakho waziva unyanzelwa kumncedi




 Think about after you started ART, have you (or a partner) had an abortion/TOP?
[Emva kokuba waqala I-ART,ukhe wena (okanye iqabane lakho) waqhomfa /
wanqamla umitho ?]
Yes=1;  No=0
Don’t know/Unsure = 9
If no ART or
male and no
partner _ 67
 If yes, can you give the reason why that pregnancy was terminated
[Ukuba ewe, ungasinika isizathu sokunqamla olomitho?]
Related to HIV-status = 1
Unrelated to HIV- status = 2
Don’t know = 9
 Was this abortion/TOP provided at a health facility?
[Ingaba okukuqhomfa/ olunqamlo mitho lwalwenziwe kwindawo yezempilo]
Yes:  at a public clinic or
hospital=1
at a private clinic or hospital=2
No, not provided at a health
facility =3;  Don’t know=9
 Think about after you started ART, have you or your partner ever felt pressurized
by a health care provider to have a termination of pregnancy?
[Cinga emva kokuba uqalise iART, Ukhe wena okanye iqabane lakho naziva





 Do you know what your most recent WHO Stage is?
[Uyazazi ukuba ukwiliphi ibakala lokugula (WHO Stage)?]
Enter Stage, I-IV
Enter 0 if participant does not
know
 Do you know what your most recent CD4 count is?
[Uyalazi ubalo lwamajoni omzimba wakho luthini (CD4 count)?]
Enter CD4 count
Enter 0 if participant does not
know
69 a) Which of the following best describes your moving around (mobility)
[Ngowuphi kule ilandelayo ocacisa ngcono ngokukwazi kwakho ukuhambahamba]
I have no problems walking =1
I have some problems walking
about=2
I am confined to bed=3
 Which of the following best describes your Daily activities ( taking care of yourself,
work, study, housework, leisure activities) [Ngowuphi kule ilandelayo ocacisa
ngcono ngokwazi kwakho ukwenza imisebenzi yemihla ngemihla (ukuphangela,
ukufunda, umsebenzi wasekhaya, nezinto ohambisa ngazo ixesha)]
(Read all options)
I have no problem performing
my usual activities=1
I have some problems with
performing my usual
activities=2
I am unable to perform my
usual activities=3
 Which of the following best describes your Pain/Discomfort
[Ngowuphi kule ilandelayo ocacisa ngcono ngeentlungu obanzo/ ukungakhululeki
komzimba]
( Read all options)
I have no pain/discomfort=1
I have moderate pain =2
I have extreme
pain/discomfort=3
 Which of the following best describes your feelings
[Ngowuphi kule ilandelayo ocacisa ngcono ngendlela oziva unodino/ uxheleke
ngayo ngokwasemphefumlweni]
(Read all options)
I am not anxious/depressed=1
I am moderately anxious
/depressed=2
I am extremely anxious
/depressed=3
NB: INTERVIEWER: Complete visual analog scale on separate page
attached
Completed=1
HIV infection disclosure & stigmatization
Now I would like to ask you some questions about who you have discussed your
HIV status with, and how you think people feel about you being HIV-positive….
Ngoku ndingathanda ukukubuza imibuzo malunga nokuba ngubani othe
wancokola naye ngokuba nentsholongwane kaGawulayo, nokuba ucinga bazive
njani ngokuba nalentsholongwane kwakho….
Have you discussed your HIV-infection with …. [ASK EACH OPTION]
Ukhe wancokola ngokusuleleka kwakho yi tsholongwane kaGawulayo no/ne..
 Any of your partners? Qabane lakho? Yes=1
No=0
Not applicable = 3
 Family members? Amulungu osapho? Yes=1
No=0












# Item Coding Skip




Not applicable = 3
 Friends? Abahlobo? Yes=1
No=0
 Other members of your community? [Abantu abangabanye basekuhlaleni?] Yes=1
No=0




 Other people? [Abanye abantu?] Specify: _______________ Yes=1
No=0
 How did most people, other than the health care providers, react when you first
told them that you were HIV positive? (read all options)
[Ucinga ukuba abantu abaninzi, ngaphandle kwabasebenzi bezempilo,








 Think about before you were HIV-positive, did you ever suffer emotional, physical
or sexual abuse from a partner?
[Cinga ngaphambi kokuba ubene ntsholongwane kaGawulayo, wakhe




 Think about after you have been HIV-positive have you ever suffered emotional,
physical or sexual abuse from a partner?
[Cinga emva kokuba ubene ntsholongwane kaGawulayo, wakhe wazifumana






ANSWERS YES, TO 79
AND/OR 80 REMEMBER TO
ASK IF WOULD LIKE TO
SPEAK WITH SOMEONE
ABOUT THIS AND ADOPT
REFERRAL PROCEDURES
 If yes, was this because of: (Read out all options.  Circle all that apply)
[Ukuba ewe, kwakenzeke ngenxa:
Your HIV status = 1
Discussing contraception=2





 Do you think that you can look forward to the future?
Ucinga ukuba wena unokujonga ngethemba kwixesha elizayo?
Yes=1
No=0
Don’t know = 9
Current fertility intentions
Now I would like to ask you some questions about having a child/children
[Ngoku ndingathanda  ukukubuza imibuzo malunga nokuba nomntwana /
abantwana]
 Think about before you were HIV-positive, what were your views about having a
child/more children?
[Cinga ngaphambi kokuba ubene ntsholongwane kaGawulayo, zazisithini













# Item Coding Skip
 Think about now, which of the following statements best describes your thinking
about you / your main partner having a child? (Read all options, circle one only)
IF CURRENTLY PREGNANT ASK ABOUT THE FUTURE
1. I want to have a child right now
2. I may want to have a child in the next 12 months
3. I may want to have a child sometime in the future
4. I have decided that I do not want to have a child in the future
5. I do not know / am unsure about whether I may want to have a child in the future
[Cinga ngokwangoku,ngowupi kule migca ilandelayo ocacisa ngcono ingcinga
zakho / zeqabane lakho ngokuba nomntwana / abantwana? ( Funda zonke
anokukhetha kuzo, ukhethe ibenye)]
1. Ndifuna ukuba nomtwana ngoku
2. Ndinafuna ukuba nomntwana kwinyanga ezi12 ezizayo
3. Ndingafuna ukuba nomtwana ngelinye ithuba kwixesha elizayo   
4. Ndigqibe ekubeni andifuni kubanamntwana kwixesha elizayo
5. Andiyazi / andiqinisekanga nokuba ndingafuna ukuba nomntwana kwixesha elizayo
Enter 1-5
 What are the reasons for your decision (in #85
Zithini izizathu zesigqibo sakho (ku #85)?
BRIEFLY Describe
 After you found out that you are HIV-positive, has your thinking about having
children now or in the future changed
[Emva kokuba wafumanisa ukuba usuleleke yintsholongwane kaGawulayo,





 If yes, how? If no, why not?
[Ukuba ewe, njani? Ukuba hayi, ngoba kutheni?]
BRIEFLY Describe
 After you started ART, has your thinking about having children now or in the
future changed?
[Emva kokuba waqalisa ukuthatha I-ART Ingaba ingcinga zakho ngokuba




If not on ART
go to _ 91
 If yes, how? If no, why not?
[Ukuba ewe, njani? Ukuba hayi, ngoba kutheni?]
BRIEFLY Describe
91 a) Is your main partner HIV-positive? Yes=1
No=0
Don’t know=9
 After you found out that you are HIV-positive, have you discussed whether or not
to have (more) children with your current main partner?
[Emva kokuba ufumanise ukuba une ntsholongwane kaGawulayo ukhe
wancokola ngokuba (nabanye) nabantwana neqabane onalo ngoku?]
Yes=1
No=0
If no or  if no
partner  _93
 If yes, how would you describe your main partner’s opinion on whether to have
(more) children?








 How little or much does your main partner’s opinion influence your decision
whether or not to have children? (read all options)
[Izimvo zeqabane lakho ingaba zinegalelo elingakanani kwisigqibo sakho sokuba





Little/not very important to
me=3
No influence at all=4
If no partner
go _94
 After you found out that you are HIV-positive, have you discussed whether or not
to have (more) children with your family?
[Emva kokuba ufumanise ukuba une ntsholongwane kaGawulayo ukhe















# Item Coding Skip
 If yes, how would you describe your family’s opinion on whether to have (more)
children?








 How little or much does your family’s opinion influence your decision whether or
not to have children? (read all options)
[Izimvo zosapho lakho ingaba zinegalelo elingakanani kwisigqibo sakho sokuba -





Little/not very important to
me=3
No influence at all=4
 How do you think most people in your community feel about HIV-positive people
who have (more) children?
[Ucinga abantu basekuhlaleni bacinga ntoni malunga nabantu abasuleleke
yintsholongwane kaGawulayo abaye babe (nabanye) nabantwana]
Most people feel positively=1
Most people feel negatively=2
Most people are neutral/don’t
care=3
Don’t know=9
 How little or much does the community’s opinion influence your decision whether
or not to have (more) children? (read all options)
[Izimvo zabahlali ingaba zinegalelo elingakanani kwisigqibo sakho sokuba -





Little/not very important to
me=3
No influence at all=4
Not applicable =5
 How would you feel if you (or your partner) became pregnant in the next few
weeks?
[Ungaziva njani xa wena (okanye iqabane lakho) unokuthi umithe kwiveki
ezimbalwa ezizayo?]
NOTE: IF SHE OR PARTNER IS PREGNANT ASK HOW SHE/HE WOULD FEEL







100 How do you think your main partner would feel if you (or your main partner)
became pregnant in the next few weeks?
[Ucinga igabane lakho lingaziva njani xa wena (okanye iqabane lakho) unokuthi
umithe kweziveki zimbalwa zizayo?]
NOTE: IF SHE OR PARTNER IS PREGNANT ASK HOW SHE/HE WOULD FEEL








partner  _ 101
101 If they knew/know you are HIV– positive, how do you think your family would feel
if you (or your partner) became pregnant in the next few weeks and they found
this out?
[Ucinga usapho lwakho lungaziva njani xa wena (okanye iqabane lakho) unokuthi
umithe kweziveki zimbalwa zizayo baze bayifumanise lonto?]
NOTE: IF SHE OR PARTNER IS PREGNANT ASK HOW SHE/HE WOULD FEEL







102 If they knew/know you are HIV– positive, how do you think people in your
community would feel if you (or your partner) became pregnant in the next few
weeks and they found this out?
[Ucinga abantu basekuhlaleni bangaziva njani xa wena (okanye iqabane lakho)







103 Would you think about adopting a child, instead of becoming pregnant, to have a
child?
[Ukhe wacinga ngoku funa umntwana ngokwasemthethweni umkhulise
njengowakho, endaweni yokumitha ukuze ube nomntwana?]
Yes=1
No=0
Don’t know/Unsure = 9
104 Would you think about caring for someone else’s child (e.g family member’s)
rather than having your own?
[Ungacinga ngokukhulisa umntwana womnye umntu (e.g womnye wamalungu
osapho) endaweni yokuba nowakho?]
Yes=1
No=0
Don’t know/Unsure = 9
Interactions with reproductive health services
We are almost finished….. Now I would like to ask some questions about whether
any health care providers have discussed having children or contraception with
you, and if so, what kinds of things they told you.
[Sele sizakufikelela ekupheleni….. Ngoku ndingathanda ukukubuza imibuzo
emalunga nokuba ukhona na umnikezi woncedo lwezempilo okhe wathetha nawe












# Item Coding Skip
105 After you became HIV-positive, have you discussed having (more) children now
or in the future with a doctor working at a hospital or clinic?
[Emva kokuba usuleleke yintsholongwane kaGawulayo, ukhe wancokola ngokuba





106 What did that doctor advise about having (more) children?
[Yintoni owakuxelela yona logqira malunga nokuba (nabanye) nabantwana?]
To have a child=1




107 For you, how unhelpful or helpful was your discussion with that doctor?










108 How little or much has that doctor’s opinion influenced your decision whether or
not to have (more) children?
[Izimvo zalogqira ingaba zinegalelo elingakanani kwisigqibo sakho sokuba-
okanye ukungabinabantwana?]
CHECK WHETHER THEY HAVE DISCUSSED THIS WITH ANYONE ELSE: LIST
NURSE, COUNSELLOR OR ANYONE ELSE AND THEN CONTINUE WITH





Little/not very important to
me=3
No influence at all=4
109 After you became HIV-positive, have you discussed having (more) children now
or in the future with a nurse working at a hospital or clinic?
[Emva kokuba usuleleke yintsholongwane kaGawulayo, ukhe wancokola ngokuba





110 What did that nurse advise you about having (more) children?
[Yintoni owakuxelela yona lomongikazi malunga nokuba (nabanye) nabantwana?]
To have a child=1




111 For you, how unhelpful or helpful was your discussion with that nurse?










112 How little or much has that nurse’s opinion influenced your decision whether or
not to have (more) children?






Little/not very important to
me=3
No influence at all=4
113 After you became HIV-positive, have you discussed having (more) children now
or in the future with a counselor working at a hospital or clinic?
[Emva kokuba usuleleke yintsholongwane kaGawulayo, ukhe wancokola ngokuba
(nabanye) nabantwana ngoku okanye kwixesha elizayo nomcebisi wezempilo




114 What did that counselor advise you about having (more) children?
[Yintoni owakuxelela yona lomcebisi wezempilo malunga nokuba (nabanye)
nabantwana?]
To have a child=1




115 For you, how unhelpful or helpful was your discussion with that counselor?
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116 How little or much has that counselor’s opinion influenced your decision whether
or not to have (more) children?






Little/not very important to
me=3
No influence at all=4
117 After you became HIV-positive, have you discussed having (more) children now
or in the future with any other person/people, at a public or private facility?
[Emva kokuba usuleleke yintsholongwane kaGawulayo, ukhe wancokola ngokuba
(nabanye) nabantwana ngoku okanye kwixesha elizayo naye nawuphina umnikezi
ncedo wezempilo, osebanza kwicandelo loluntu okanye kwelabucala?]






118 What did that person/people advise you about having (more) children?
[Yintoni owakuxelela yona lomnikezi ncedo malunga nokuba (nabanye)
nabantwana?]
To have a child=1




119 For you, how unhelpful or helpful was your discussion with that person/people ?










120 How little or much has that person’s/people’s opinion influenced your decision
whether or not to have (more) children?






Little/not very important to
me=3
No influence at all=4
Now, I’ll ask some questions about what providers discussed with you about
contraception
[Ngoku ndizakukubuza imibuzo malunga nokuba bancokole bathini abanikezi
boncedo malunga nokucwangcisa]
121 After you became HIV-positive, have you discussed using contraception with a
doctor working at a hospital or clinic?
[Emva kokuba usuleleke yintsholongwane kaGawulayo, ukhe wancokola
ngokusebenzisa ucwangciso nogqira, osebanza esibhedlele okanye eklinik?]
INTERVIEWER TO CHECK WHETHER THEY DISCUSSED A METHOD OTHER




122 What did that doctor advise you about using contraception?
[Yintoni owakuxelela yona logqira malunga nokusebenzisa ucwangciso?]
To use contraception=1




123 For you, how unhelpful or helpful was your discussion with that doctor?










124 How little or much has that doctor’s opinion influenced your (your partner’s)
decision to use contraception?
[Izimvo zalogqira ingaba zinegalelo elingakanani kwisigqibo sakho (seqabane
lakho) sokusebenzisa ucwangciso?]
CHECK WHETHER THEY HAVE DISCUSSED THIS WITH ANYONE ELSE: LIST
NURSE, COUNSELLOR OR ANYONE ELSE AND THEN CONTINUE WITH





Little/not very important to
me=3
No influence at all=4
125 After you became HIV-positive, have you discussed using contraception with a
nurse working at a hospital or clinic?
[Emva kokuba usuleleke yintsholongwane kaGawulayo, ukhe wancokola















# Item Coding Skip
126 What did that nurse advise you about using contraception?
[Yintoni owakuxelela yona lomongikazi malunga nokusebenzisa ucwangciso?]
To use contraception=1




127 For you, how unhelpful or helpful was your discussion with that nurse?










128 How little or much has that nurse’s opinion influenced your (your partner’s)
decision to use contraception?
[Izimvo zalomongikazi ingaba zinegalelo elingakanani kwisigqibo sakho





Little/not very important to
me=3
No influence at all=4
129 Since you became HIV-positive, have you discussed using contraception with a
counselor working at a hospital or clinic?
[Emva kokuba usuleleke yintsholongwane kaGawulayo, ukhe wancokola





130 What did that counselor advise you about using contraception?
[Yintoni owakuxelela yona lomcebisi wezempilo malunga nokusebenzisa
ucwangciso?]
To use contraception=1




131 For you, how unhelpful or helpful was your discussion with that counselor?










132 How little or much has that counselor’s opinion influenced your (your partner’s)
decision to use contraception?
[Izimvo zalomcebisi wezempilo ingaba zinegalelo elingakanani kwisigqibo sakho





Little/not very important to
me=3
No influence at all=4
133 After you became HIV-positive, have you discussed using contraception with any
other person/people, at a public or private facility?
[Emva kokuba usuleleke yintsholongwane kaGawulayo, ukhe wancokola
ngokusebenzisa ucwangciso naye nawuphina umsebenzi wezempilo, osebanza
kwicandelo loluntu okanye kwelabucala?]






134 What did that person/people advise you about using contraception?
[Yintoni owakuxelela yona lomcebisi wezempilo malunga nokusebenzisa
ucwangciso?]
To use contraception=1




135 For you, how unhelpful or helpful was your discussion with that person/people?
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136 How little or much has that person’s/people’s opinion influenced your (your
partner’s) decision whether or not to use contraception?
[Izimvo zalomnikezi ncedo ingaba zinegalelo elingakanani kwisigqibo sakho





Little/not very important to
me=3
No influence at all=4
Reproductive health options
137 After you found out you had HIV, has a nurse, counselor, doctor or person/people
at the clinic/hospital ever talked to you about abortion/termination of pregnancy
(TOP)?
[Emva kokuba ufumanise ukuba une ntsholongwane kaGawulayo, ukhona
umongikazi, umcebisi wezampilo okanye ugqira osebenza eklinik / esibhedlele




138 If yes, what type of person discussed TOP with you? (circle as many as apply)




Doctor at public facility=3
GP/Doctor at private facility=4
Other provider=5
Specify:___________
139 If you or your partner became pregnant now, how likely or unlikely would you/your
partner be to have an abortion/TOP?[Ukuba wena okanye iqabane lakho
ningamitha ngoku, kulindeleke kangakanani ukuba wena / iqabane lakho
ningaqhomfa / TOP]
Very likely =1: Likely=2
Maybe/would consider=3
Unlikely= 4; Definitely not=5
Don’t know/unsure=9
140 After you found out you had HIV, has a nurse, counselor or doctor working at the
clinic/hospital ever talked to you about emergency contraception (EC)?
[Emva kokuba ufumanise ukuba une ntsholongwane kaGawulayo, ukhona
umongikazi, umcebisi wezempilo okanye ugqira osebenza eklinik / esibhedlele




141 If yes, what type of person discussed EC with you? (circle as many as apply)
[Ukuba ewe, loluphi udidi lomnikezi  ncedo wezempilo owancokola nawe
ngocwangciso olukhawulezileyo?]
Nurse= 1; Counselor= 2
Doctor at public facility=3
GP/Doctor at private facility=4
Other provider=5
Specify:___________
142 If you had unprotected sex right now, how likely or unlikely would you/your partner
be to use EC?
[Ukuba ungabelana ngesondo ungazikhuselanga ngoku, kulindeleke kangakanani
ukuba wena / iqabane lakho nisebenzise i-EC?]
Very likely=1; Likely=2
Maybe/would consider= 3
Unlikely= 4; Definitely not= 5
Don’t know/unsure=9
143 After you found out you had HIV, has a nurse, counselor, doctor, or
person/people at the clinic/hospital ever talked to you about sterilization
[Emva kokuba ufumanise ufumanise ukuba unentsholongwane kaGawulayo,
ukhona umongikazi, umcebisi wezempilo, ugqira okanye umntu/abantu
esibhedlele /ekliniki okhe wathetha nawe malunga nokuvala inzala?]
Yes=1
No=0
144 Did you ever feel pressurized to have sterilisation by any of these people? [Wakhe
waziva unyanzeliswa ukuba uvale inzala nanguye nawuphi na kwababantu?]
Yes=1
No=0
145 Since you found out you had HIV, has a nurse, counselor or doctor or
person/people at the clinic/hospital ever told you about Pap smears and/or
cancer of the womb? [Oko wathi wafumanisa ukuba une ntsholongwane
kaGawulayo, ukhona umongikazi, umcebisi wezempilo okanye ugqira osebenza





146 If yes, what type of person discussed Pap smears/cervical cancer with you?
(circle as many as apply)
[Ukuba ewe, loluphi udidi lomnikezi ncedo wezempilo owancokola xnawe nge Pap
smear / umhlaza wesibeleko?]
Nurse= 1; Counselor= 2
Doctor at public facility=3
GP/Doctor at private facility=4
Other provider=5
Specify:___________
147 Since you found out you had HIV, has a nurse, counselor, doctor or other
person/people at the clinic/hospital ever told you about health services that can
help people to have children when they are having difficulty (they are trying
to have children but can not)?
[Oko wathi wafumanisa ukuba une ntsholongwane kaGawulayo, ukhona
umongikazi, umcebisi wezempilo okanye ugqira osebenza eklinik / esibhedlele
owakhe wakuxelela ngoncedo lwezempilo elinokuthi luncede abantu
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148 If yes, what type of person discussed these services with you? (circle as many as
apply) [Ukuba ewe, loluphi udidi lomnikezi ncedo wezempilo owancokola nawe
ngoluncedo?]
Nurse=1; Counselor=2
Doctor at public facility=3
GP/Doctor at private facility=4
Other provider=5
Specify:___________
(e.g. support group, TAC etc.)
148 b)f there was a way that you/your partner could be helped by a
health care provider  to become pregnant, that did not involve risking
infecting a male partner with HIV (and through medication to prevent
infant infection, the chances of infecting a baby was small), would you
be interested in this? [Ukuba ibikhona indlela yokuba wena/iqabane lakho
uncedwe ngabanikezi ncedo bezempilo ukuba ukhulelwe, ungakhange wabeka
iqabane eliyindoda emngciphekweni wokosuleleka yintsholongwane kaGawulayo
(futhi ukuba ngamachiza okukhusele usana ekosulelekeni, bekunokuthi




149 After you found out you had HIV, has a nurse, counselor, doctor or person/people
at the clinic/hospital ever discussed using condoms with you? [Emva kokuba
ufumanise ukuba une ntsholongwane kaGawulayo, ukhona umongikazi, umcebisi





150 If yes, what type of person discussed condom use with you? (circle as many as
apply)
[Ukuba ewe, loluphi udidi lomnikezi ncedo wezempilo owancokola nawe
ngokusetyenziswa kwekondom? (ketha zonke ezingenayo)]
Nurse=1
Counselor=2
Doctor at public facility=3
GP/Doctor at private facility=4
Other provider=5
Specify:___________
151 If yes, what did they tell you about the health benefits of condom use?
[Ukuba ewe, bakuxelele ntoni malunga nokusetyenziswa kwekondom]









152 Do you think that you may like to discuss issues regarding childbearing or
parenthood more in the future with a health care provider?
[Ucinga ukuba ungathanda ukucokola ngemibandela enxulumene nokuzala
abantwana nangaphezulu kwixesha elizayo?]
Yes=1
No=0
153 If yes, with whom would you like to discuss these issues? (Read all, circle as many
as apply)










154 What specific issues would you like to discuss with a health care provider?
[Yeyiphi imiba ongathanda ukuncokola ngayo nomnikezi woncedo lwezempilo]
BRIEFLY Describe (open-
ended)
155 Are there any issues that we have not asked you about, regarding your thinking
around childbearing and/or contraception or parenthood, that you would like to
raise?
[Ingaba ikhona imibandela esingakubuzanga ngayo ngokunxulumene noluvo lwakho
ngokuzala no/okanye ngokucwangcisa, ongathanda ukuyiphakamisa?]
BRIEFLY Describe (open-
ended)












Appendix E: Additional Tables and Figures
Appendix E.1: Effect of HIV-positive diagnosis on NBCU, McNemar’s Test
P-Value Odds Ratio 95% CI
Before vs. After <0.0001 0.2340 (0.1095 - 0.4578)
After vs. Current 0.5966 0.7778 (0.3580 – 1.6552)
Before vs. Current <0.0001 0.2727 (0.1431 – 0.4896)
Appendix E.2: Summary of non-users of NBC, by time period
Before Diagnosis After Diagnosis Current Use
n % n % n %
No NBCU 22 12.2 58 32.2 62 34.4
Appendix E.3: Frequencies of NBCU, before and after diagnosis, and current use
Frequency Percent














No Use After, No
Current Use
44 24.44
No Use After, Current
Use
14 7.78








No Use Before, No
Use After
11 6.11
No Use Before, Use
After
11 6.11
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Appendix E.5: Logistic regression model building process for non-use of NBC by women with current fertility intentions
Variable Crude Models Model 1 (All Variables)
(n=20)^^^




baseline = 2 years)
0.91 (0.61-1.36)
Years Since Diagnosis (per
year, baseline = 0 years)
0.78 (0.53-1.17)
Living Children*
    0 Children







Sexual Partners in Past 6
Months (1+ vs. 0)
^^
Use of ART 0.33 (0.05-2.24)









^-3 failures and 0 successes completely determined
^^-dropped due to collinearity
^^^-8 failures and 2 successes completely determined
**-In comparison to having 2+ living children












Appendix E.6: Logistic regression model building process for non-use of NBC by women with future fertility intentions
Variable Crude Models Model 1 (All Variables)
(n=47)
Age (per year, baseline =
20 years)
0.96 (0.86-1.08) 0.97 (0.79-1.18)
Education (per year,
baseline = 2 years)
0.92 (0.71-1.18) 0.61 (0.30-1.24)
Years Since Diagnosis
(per year, baseline = 0
years)
0.80 (0.62-1.05) 0.87 (0.52-1.46)
Living Children*
    0 Children








2.27 (0.60-8.64) 6.04 (0.42-86.95)
Household Income
(R1000+ vs. <R1000)
2.05 (0.54-7.79) 1.40 (0.17-11.27)
Sexual Partners in Past 6
Months (1+ vs. 0)
0.52 (0.07-4.04) 0.69 (<0.01-62.78)
Use of ART 0.18 (0.05-0.65)^ 0.06 (<0.01-0.73)^
NBCU Before Diagnosis 0.90 (0.19-4.32) 0.51 (0.05-5.27)
Condom Use After
Diagnosis








*-In comparison to having 2+ living children
**-In comparison to not being in a sexual relationship
^-p-value <0.05



































































































































































































































































































































































































































































Appendix E.8: Logistic regression model building process for non-use of NBC by women not using ART
Variable Crude Models Model 1 (All
Variables) (n=70)
Age (per year, baseline = 20
years)
1.02 (0.97-1.08) 1.05 (0.96-1.15)
Education (per year,
baseline = 2 years)
0.93 (0.75-1.14) 0.97 (0.73-1.27)
Years Since Diagnosis (per
year, baseline = 0 years)
0.93 (0.73-1.17) 1.03 (0.75-1.40)
Living Children*
    0 Children







0.39 (0.12-1.29) 0.46 (0.09-2.42)
Household Income (R1000+
vs. <R1000)
0.45 (0.17-1.23) 0.73 (0.19-2.78)
Sexual Partners in Past 6
Months (1+ vs. 0)
0.22 (0.06-0.88)^ 0.34 (0.05-2.09)
NBCU Before Diagnosis 1.06 (0.20-5.65) 0.96 (0.13-7.16)
Condom Use After
Diagnosis















*-In comparison to having 2+ living children
**-In comparison to not being in a sexual relationship













Appendix E.9: Logistic regression model building process for non-use of NBC by women using ART
Variable Model 1 (Crude) Model 2 (All
Variables) (n=98)
Age (per year, baseline = 20
years)
1.02 (0.95-1.09) 1.09 (0.98-1.21)
Education (per year,
baseline = 2 years)
0.87 (0.68-1.12) 0.83 (0.59-1.15)
Years Since Diagnosis (per
year, baseline = 0 years)
0.86 (0.70-1.06) 0.82 (0.64-1.05)
Living Children*
    0 Children







1.06 (0.31-3.64) 0.89 (0.20-4.02)
Household Income (R1000+
vs. <R1000)
1.26 (0.47-3.37) 1.17 (0.36-3.78)
Sexual Partners in Past 6
Months (1+ vs. 0)
0.84 (0.30-2.34) 0.44 (0.06-3.37)
NBCU Before Diagnosis 1.09 (0.28-4.29) 1.12 (0.22-5.80)
Condom Use After
Diagnosis















*-In comparison to having 2+ living children
**-In comparison to not being in a sexual relationship
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Editorial Policies
Contraception invites concise reports of original research in the experimental and
clinical aspects of all areas of contraception. The purpose of this journal is to provide
a medium for the rapid communication of advances and new knowledge in this
important field. The Editor anticipates receiving manuscripts from workers in the
following areas of research: chemistry, biochemistry, physiology, endocrinology,
biology, the medical sciences, and demography. Publication of original papers within
90 days of manuscript receipt is planned. Authors will be advised of disposition of the
manuscript within 30 days of receipt.
Manuscript Submission Process ONLINE
All manuscripts must be submitted electronically through the Elsevier Editorial
System website (www.ees.elsevier.com/contraception). Select: "New Manuscript".
Author guidance is provided for creating and uploading all files and data. The system
automatically generates an electronic (PDF) proof, which is then sent to the Editorin-
Chief and to designated reviewers. All correspondence about submitted manuscripts
also will be handled by e-mail through the EES.
The requirement for manuscripts submitted to Contraception conform to the "Uniform
Requirements for Manuscripts Submitted to Biomedical Journals" established by the
International Committee of Medical Journal Editors and published in Annals of
Internal Medicine 1988; 108:258-65.
Trial and research guidelines. The following guidelines must be adhered to when
formulating the study. Upon submission of the manuscript, authors are to indicate the
type of trial/research used on the Author Checklist.
    * Randomized controlled trials. Authors are to consult the CONSORT statement.
(Moher D, Schulz KF, Altman D, for the CONSORT Group. The CONSORT
Statement: Revised recommendations for improving the quality of reports of parallel-
group randomized trials. JAMA 2001;285:1987-91) A flow-chart as a figure must be
submitted with the manuscript. www.consort-statement.org
    * Meta-analysis and systematic reviews of randomized controlled trials. Authors
are to consult the QUOROM statement. (Moher D, Cook DJ, Eastwood S, Olkin I,
Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of
randomized controlled trials: the QUOROM statement. Quality of Reporting of Meta-
Analyses. Lancet 1999;354:1896-900.) www.thelancet.com
    * Meta-analysis and systematic review of observational studies. Authors are to
consult the MOOSE guidelines. (Stroup DF, Berlin JA, Morton SC, et. al., for the
Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. Meta-
analysis of observational studies in epidemiology: A proposal for reporting. JAMA
2000;283:2008-12." www.jama.ama-assn.org
    * Diagnostic tests. Authors are to consult the STARD Initiative. (Bossuyt, PM,
Reitsma, JB, Bruns, DE, et. al. Towards complete and accurate reporting of studies of













Previous publication. If a report by the same author(s) has been previously published
in any medium that deals in any respect whatever with the same patients, same
animals, same laboratory experiments, or same data, in part or in full, as those
reported in the manuscript being submitted, two reprints of the article or two copies of
the manuscript, be it a full-length report or an abstract, must be submitted with the
manuscript. The author(s) should inform the Editor of the circumstances, similarities,
and differences of the reports. This requirement also applies to the submission of a
manuscript in which a few different patients, animals laboratory experiments, or data
were added to those reported in a previous publication or in a submitted or accepted
manuscript. Articles previously published in another language will not be considered.
Human and animal experimentation. It is assumed by the Editor that manuscripts
emanating from a particular institution are submitted with the approval of the
requisite authority. Human experimentation that requires local institutional approval
must have this approval before the experiment is started and approval must be so
indicated in the Methods section of the submitted manuscript. Reports of experiments
on animals must state in the Methods section of the manuscript that the guidelines for
the care and use of the animals approved by the local institution were followed. The
species of nonhuman animals must be named in the title, abstract, and key words of
the manuscript.
Authorship. For manuscripts with two or more authors, each author must qualify by
having participated actively and sufficiently in the study that is being performed and
reported. The inclusion of each author in the authorship list of a report is based only
(1) on substantial contributions to (a) concept and design, or analysis and
interpretation of data and (b) drafting the manuscript or revising it critically for
important intellectual content; and (2) on final approval by each author of the version
of the manuscript. Conditions 1 (a and b) and 2 must both be met. Others contributing
to the work should be recognized separately in an Acknowledgment. In the covering
letter that accompanies the submitted manuscript, it must be confirmed that all authors
fulfilled both conditions.
English language manuscripts should be sent directly to: Shirley Davenport,
Contraception Editorial Office, 25313 Via Calinda, Valencia, CA 91355, USA; Tel:
661-259-9566; Fax: 661-255-1480. Authors outside the United States should address
manuscripts to a corresponding editors in their own country. Authors in countries not
represented by a corresponding editors should send their manuscripts directly to the
Editor in California.
Preparation of Manuscripts. The electronic manuscript, tables, and figures must be
submitted to the Journal at www.ees.elsevier.com/contraception. Submit figures
online in a separate file in EPS, JPEG, or TIFF format (minimum 300 dpi). Figures
should not be embedded in the manuscript document. If a figure has been previously
published, by you or by others, obtain permission and acknowledge fully in the figure













Manuscripts must be typed double-spaced. Also include five or six keywords and a
short running title.
A manuscript length of 5-9 pages, including tables, figures, and references is
suggested. Where warranted, longer papers may be accepted.
Title Page. The text of the article should include the following: a STRUCTURED
ABSTRACT (with the following subheadings: Background, Study Design, Results,
Conclusions) (approximately 150 words) INTRODUCTION, MATERIALS and
METHODS, RESULTS, DISCUSSION, and ACKNOWLEDGMENT/ NOTES.
Text. The text of the article should include the following: ABSTRACT
(approximately 150 words), INTRODUCTION, MATERIALS and METHODS,
RESULTS, DISCUSSION, and ACKNOWLEDGMENT/FOOTNOTES (this is
where the author name and address for reprint requests should be listed).
Figures. All figures (photographs, drawings, diagrams, charts) should be clear, easily
legible and cited consecutively by Arabic numerals in the text (Figure 1, Figure 2,
etc.). Legends should contain sufficient detail to permit figure interpretation without
reference to the text. Units should be indicated in the figures. The cost of color
reproduction in the print journal is $400 for the first figure on a page. The cost for
each additional color figure on the page is $150. Multi-part figures are considered one
figure. All color figures will appear on the web site (www.contraceptionjournal.org)
at no cost to the authors.
Tables. Tables must be concise, as simple as possible, and cited consecutively by
Arabic numerals in the text (Table 1, Table 2, etc.). Each table should be titled and
submitted as a separate file. The title of each table should clearly indicate the nature
of the contents. Sufficient detail should be included in the table footnote to facilitate
interpretation.
References. References must adhere to the specifications of the "Uniform
Requirements for Manuscripts Submitted to Biomedical Journals" promulgated by the
International Committee of Medical Journal Editors.
References are numbered consecutively in the order in which they appear in the text.
Citations should be on the line of text enclosed in brackets and the period or comma
should follow the reference at the end of the sentence.
Each reference must be cited. Referenced articles must have been published in peer-
review publications that are generally accessible. Unpublished data, personal
communications, papers presented at meetings and symposia, abstracts, and
manuscripts "submitted for publication" are not acceptable as references. Information
from such sources may be cited, if necessary, in the text with the sources given in
parentheses (e.g., unpublished observations). Papers "in press" may be cited, but must
include the journal title, Digital Object Identifier (DOI) and year (if known). Books
must include the publisher and year of publication (if known).
References should be listed in numerical order in the Reference Section, immediately












brackets, with no period after the brackets. Journal names should be abbreviated
according to the style of MEDLINE, National Library of Medicine. Please note that
no periods are used after the authors' initials or after journal abbreviations. "et al." is
used when there are more than six authors. There is a period at the end of each
reference. The type and punctuation of references consistent with the "Uniform
Requirements" are illustrated as follows:
Journal article, up to six authors:
List all authors when six or fewer.
Baskett TF, Allen AC, Gray JH, Young DC, Young LM. Fetal biophysical profile and
perinatal death. Obstet Gynecol 1987;70:357-60.
Journal article, more than six authors:
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Book with a volume number:
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Book, 1978: 1-288. (Lees DH, Singer A. Color atlas of gynecological surgery; vol 2).
Letters to the Editor. This section of the journal is set aside for critical comments
directed to a specific article that has recently been published in the journal. Letters
should be brief (400 words), double-spaced, and limited to a maximum of 5 citations.
The letters and replies should be prepared according to journal format. Illustrative
material is accepted only with permission of the Editor. With your correspondence,
please include your complete mailing address, telephone and fax numbers, and E-mail
address is available.
The Editor reserves the right to shorten letters, delete objectionable comment, and
make other changes to comply with the style of the journal. Submit your letters on
line to http://www.ees.elsevier.com/contraception .












Please note that all manuscripts and revisions should be submitted electronically.
1) Please send papers in MS Word format or a compatible program.
2) All design considerations for typefaces, page layout, and artwork will be handled
by the publisher after receipt of the electronic manuscript. There is no need for the
author to input special typesetting codes. Please avoid extra formatting (such as
centering heads), embedding footnotes in a hidden field, or using a bibliographic or
footnote format for reference lists.
3) Be especially sure to distinguish between the letter O and I and the number 0 and 1,
respectively.
4) A "hard return" results from tapping the keyboard's Enter key. Use a hard return
only to end a paragraph, or for titles, subheads, separate items on a list, etc. Rely on
the program's soft return within paragraphs, list items, etc.
5) Use your word processor's capabilities for the following text attributes:
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Text that will be italic in published form may be keyboarded italic or underlined.
6) Do not use your word processor's hyphenation capabilities. Do not right justify
text. Use two hyphens for en-dashes; 3 hyphens for em-dashes.
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